var title_f24_55_25456="Buccal hyperpigmentation";
var content_f24_55_25456=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F56401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F56401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Buccal hyperpigmentation due to ACTH excess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lips and gums of a 32-year-old man demonstrating hyperpigmentation of the buccal mucosa along the line of dental occlusion (an area of repeated trauma) and of the gums (in the area of chronic inflammatory periodontal disease). The high plasma ACTH concentrations responsible for the hyperpigmentation were due in this case to primary adrenal insufficiency; similar changes can be seen in patients with ACTH-dependent Cushing's syndrome or Nelson's syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Williams Textbook of Endocrinology, 8th ed, Foster, DW, Wilson, JD (Eds), WB Saunders, Philadelphia, 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_55_25456=[""].join("\n");
var outline_f24_55_25456=null;
var title_f24_55_25457="2D TTE Subcostal view normal IVC";
var content_f24_55_25457=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Two-dimensional transthoracic echocardiogram (2D TTE) from the subcostal view showing a normal inferior vena cava (IVD) during respiration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 198px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The subcostal view in a normal subject shows the inferior vena cava (IVC). Left panel: Prior to inspiration, the normal diastolic IVC diameter (arrows) is less than 20 mm. Right panel: During inspiration, the IVC collapses to less than 50 percent of its original diameter.",
"    <div class=\"footnotes\">",
"     L: liver.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_55_25457=[""].join("\n");
var outline_f24_55_25457=null;
var title_f24_55_25458="Normal thromboelastography and parameters";
var content_f24_55_25458=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F58281%7ESURG%2F58977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F58281%7ESURG%2F58977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Normal thromboelastography and parameters",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal citrated rapid TEG tracing with normal ACT, R time, K time, alpha angle, MA, G, and LY30.",
"    <div class=\"footnotes\">",
"     R (reaction time): time from sample placement or activation until the tracing amplitude reaches 2 mm; K (clot formation time): time elapsed between the R-time and the point where the tracing amplitude reaches 20 mm; alpha angle: angle between the middle line of the tracing and a tangential line to the developing \"body\" of the tracing; MA (maximal amplitude): the maximal amplitude reached after clot initiation; G: a calculated measure of total clot strength based on amplitude; LY30: the amount of clot lysis detected 30 minutes after the maximal amplitute (MA) is reached; SP (split point): time from sample placement (or activation with an exogenous procoagulant) until the earliest detectable resistance.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Hypercoagulability",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Citrated rapid-TEG reflecting hypercoagulability. The red tracing indicates a normal study.",
"    <br>",
"     This study shows a shortened to normal ACT, R time, and K time, reflecting enzymatic hypercoagulability; high alpha angle, MA, and G, reflecting platelet hypercoagulability and/or excessive fibrin deposition; normal LY30. To distinguish the relative contribution of platelet hypercoagulability and excessive fibrin deposition, one would need to perform TEG platelet mapping or RoTEM&reg; fibrin function testing.",
"     <div class=\"footnotes\">",
"      R (reaction time): time from sample placement or activation until the tracing amplitude reaches 2 mm; K (clot formation time): time elapsed between the R-time and the point where the tracing amplitude reaches 20 mm; alpha angle: angle between the middle line of the tracing and a tangential line to the developing \"body\" of the tracing; MA (maximal amplitude): the maximal amplitude reached after clot initiation; G: a calculated measure of total clot strength based on amplitude; LY30: the amount of clot lysis detected 30 minutes after the maximal amplitute (MA) is reached; SP (split point): time from sample placement (or activation with an exogenous procoagulant) until the earliest detectable resistance.",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_55_25458=[""].join("\n");
var outline_f24_55_25458=null;
var title_f24_55_25459="TR and stenosis four chamber color Doppler echo";
var content_f24_55_25459=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/70050/4chctrts_conv.mp4?title=TR+and+stenosis+four+chamber+color+Doppler+echo\" style=\"width:328px;height:248px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tricuspid regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 238px; height: 438px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The four chamber view from a 2-D echocardiogram with color flow Doppler shows tricuspid regurgitation. The regurgitant \"jet\" is directed toward the posterior wall of the right atrium which is enlarged. There is also a high velocity, turbulent, and narrow echo into the right ventricle during diastole suggesting the presence of tricuspid stenosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_55_25459=[""].join("\n");
var outline_f24_55_25459=null;
var title_f24_55_25460="Fluorometholone: Patient drug information";
var content_f24_55_25460=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fluorometholone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/49/41748?source=see_link\">",
"     see \"Fluorometholone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/47/23283?source=see_link\">",
"     see \"Fluorometholone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F172523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flarex&reg;;",
"     </li>",
"     <li>",
"      FML Forte&reg;;",
"     </li>",
"     <li>",
"      FML&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F172524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Flarex&reg;;",
"     </li>",
"     <li>",
"      FML Forte&reg;;",
"     </li>",
"     <li>",
"      FML&reg;;",
"     </li>",
"     <li>",
"      PMS-Fluorometholone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691836",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat eye swelling.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702141",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fluorometholone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703763",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have herpes, viral, or yeast infections of the eye.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696431",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More eye pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697994",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A wound that does not heal.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705561",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Suspension:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705468",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Ointment:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place drug inside the lower lid. Close the eye for 1 to 2 minutes. Roll eyeball around.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695617",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 10 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12483 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.65.66-BC5B390E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_55_25460=[""].join("\n");
var outline_f24_55_25460=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172523\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172524\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016693\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016692\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016697\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016698\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016700\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016695\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016696\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016701\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016702\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/49/41748?source=related_link\">",
"      Fluorometholone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/47/23283?source=related_link\">",
"      Fluorometholone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_55_25461="Gadoversetamide: Drug information";
var content_f24_55_25461=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gadoversetamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/38/33379?source=see_link\">",
"    see \"Gadoversetamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3414728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      OptiMARK&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F15572566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      OptiMARK&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3414732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent;",
"     </li>",
"     <li>",
"      Gadolinium-Containing Contrast Agent;",
"     </li>",
"     <li>",
"      Radiological/Contrast Media (Nonionic, High Osmolality);",
"     </li>",
"     <li>",
"      Radiological/Contrast Media, Paramagnetic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3414760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      CNS or liver lesions",
"     </b>",
"     : I.V.: 0.1 mmol/kg (0.2 mL/kg)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3414761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F3414762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose adjustment is not recommended; however, use with caution. Risk for NSF development increases as renal function decreases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemodialysis: If administered to patients already receiving hemodialysis, consider prompt hemodialysis following exposure (eg, within 3 hours) (Kuo, 2007). Data has been shown hemodialysis enhances gadolinium elimination with average gadolinium excretory rates of 78%, 96%, and 99% in the first, second, and third hemodialysis sessions, respectively (Kuo, 2007; Okada, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peritoneal dialysis: Likely to be less efficient at clearing gadolinium (Joffe, 1998; Kuo, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F3414763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pharmacokinetics were not significantly altered; dose adjustment is not recommended.",
"    </p>",
"    <p style=\"text-indent:0em;margin-right:2em;\">",
"     Perioperative liver transplantation period or hepatorenal syndrome (with concomitant acute renal insufficiency, of any severity): Use is contraindicated (Canadian labeling).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3414767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     OptiMARK&reg;: 330.9 mg/mL (5 mL, 10 mL, 15 mL, 20 mL, 30 mL, 50 mL) [contains calcium chloride dihydrate 0.7 mg/mL, versetamide sodium 28.4 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3414730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3414764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer as rapid bolus injection over 1-2 mL/second. Flush line with NS 5 mL to ensure complete injection of medium. Imaging should be completed within 60 minutes of injection.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3414733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contrast medium for magnetic resonance imaging (MRI) to visualize CNS lesions with abnormal vascularity in the brain, spine, and associated tissues and to visualize liver lesions with abnormal vascularity in patients highly suspect for liver structural abnormalities",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F12932490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contrast medium for magnetic resonance angiography (MRA)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3414743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Vasodilation (6%), QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation (&ge;61 msec, 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (9%), dizziness (4%), pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Taste perversion (6%), nausea (3%), abdominal pain (2%), diarrhea (2%), dyspepsia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site reaction (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (2%), weakness (2%), back pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Rhinitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening: Agitation, allergic reaction, amblyopia, anorexia, anxiety, appetite increased, arrhythmia, arthralgia, asthma, chest pain, confusion, conjunctivitis, constipation, cough, creatinine increased, depersonalization, diaphoresis, diplopia, dry skin, dysphagia, dyspnea, dystonia, dysuria, edema, epistaxis, eructation, erythema multiforme, facial edema, fever, flatulence, flu-like syndrome, hallucinations, hemoptysis, hyperacusis, hypercalcemia, hyper-/hypoglycemia, hyper-/hypotension, hypertonia, hypoesthesia, hyponatremia, injection site edema, injection site reactions, laryngismus, leg cramps, malaise, mucous membrane discharge, myalgia, myasthenia, neck pain, neck rigidity, nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy (NSF/NFD), nervousness, oliguria, pallor, palpitation, parosmia, pelvic pain, pharyngitis, pruritus, rash (maculopapular and vesiculous bullous), salivation increased, seizure, sinusitis, somnolence, spasm, syncope, tachycardia, thirst, thrombocytopenia, thrombophlebitis, tinnitus, tremor, urinary frequency, urticaria, vasospasm, vertigo, voice alteration, vomiting, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3415128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any gadolinium-based contrast agent, versetamide, or any component of the formulation; chronic severe kidney disease (GFR &lt;30 mL/min/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ); acute kidney injury",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Acute renal insufficiency (regardless of severity) due to hepatorenal syndrome or during the perioperative liver transplantation period",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3414739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity, including anaphylactic reactions (rare), may occur; appropriate equipment (eg, ventilator) and emergency medications (eg, epinephrine) should be available during use. Delayed reactions may also occur (within several hours of administration). Patients with a history of allergic reactions and/or bronchial asthma may be at an increased risk for developing hypersensitivity reactions; use caution in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrogenic systemic fibrosis:",
"     <b>",
"      [U.S. Boxed Warning]: Gadolinium-based contrast agents (GBCAs) exposure may increase the risk for nephrogenic systemic fibrosis (NSF) in patients with renal impairment; avoid use unless GBCA enhanced imaging is essential for diagnostic purposes. Use is contraindicated in patients with acute kidney injury or chronic, severe renal disease (GFR &lt;30 mL/minute/1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      ).",
"     </b>",
"     The risk appears lower in patients with moderate, chronic renal disease (GFR 30-59 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ) and little, if any, in patients with mild, chronic renal disease (GFR 60-89 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ). NSF, a potentially fatal disease, affects the skin, muscle, and internal organs and can occur days to months after exposure. All patients should be screened for renal dysfunction prior to administration; estimate GFR in patients at risk for chronic renal disease (diabetes, hypertension, age &gt;60 years). In patients at risk of NSF, do not exceed the recommended dosage and allow sufficient time (ie, several half-lives) for elimination prior to readministration (avoidance of readministration is preferred). In patients receiving hemodialysis, consider prompt initiation of hemodialysis following administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; contraindicated in patients with acute kidney injury or chronic, severe renal impairment (GFR &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ). Dose-dependent worsening of renal function or acute renal failure has occurred in patients with renal insufficiency, generally within 48 hours following administration. Evaluate renal function in patients with renal impairment prior to use; consider follow-up monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sickle cell anemia: In",
"     <i>",
"      in vitro",
"     </i>",
"     studies, deoxygenated sickle erythrocytes align perpendicular to a magnetic field; the enhancement of magnetic moment by contrast agents may potentiate this alignment possibly resulting in vaso-occlusive complications",
"     <i>",
"      in vivo",
"     </i>",
"     . Sickling, possibly leading to vaso-occlusion, has been reported (rare, case reports) with use of hyperosmolar contrast solutions; believed to result from red blood cell dehydration. Use in patients with sickle cell anemia or other hemoglobinopathies has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Repeat doses: Safety of repeat doses has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Scan interpretation: Use caution when interpreting a contrast-enhanced scan in the absence of a companion unenhanced noncontrast MRI.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5562963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Contrast Media (Non-ionic) may enhance the potential for allergic or hypersensitivity reactions to Aldesleukin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3414734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3414735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Gadolinium-based contrast agents cross the placenta in humans. Gadolinium-based agents should not routinely be administered to pregnant women (Expert Panel on MR Safety, 2013; Wang, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3414737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3414738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gadolinium-based contrast agents are excreted in breast milk in small amounts and oral absorption is poor; information specific to gadoversetamide is not available. Although some sources state breast-feeding may be continued, the manufacturer recommends discontinuing breast-feeding and discarding breast milk for 72 hours following administration. Contrast media may temporarily alter the taste of breast milk (Tremblay, 2012; Webb, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (OptiMARK Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     330.9 mg/mL (15 mL): $67.32",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3950496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs of hypersensitivity (during and for several hours after procedure); renal function (prior to administration); short- and long-term monitoring of signs and symptoms of NSF (eg, burning, itching, swelling, hardening and/or tightening of skin, joint stiffness, deep hip or rib bone pain, muscle weakness, limited range of motion, and/or yellowed/raised spots on whites of eye)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      OptiMARK (AR, BE, CZ, DK, GR, HN, IE, NL, PE, PT, PY, SE, SG, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3414753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gadoversetamide is a paramagnetic agent formed by the chelation of gadolinium and versetamide. Exposure to an external magnetic field induces a large local magnetic field in exposed tissues. This local magnetism disrupts water protons in the vicinity, resulting in a change in proton density and spin characteristics, which can be detected by the imaging device.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3414755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 162 &plusmn; 25 mL/kg; does not cross intact blood-brain barrier; distribution half-life: 13.3 &plusmn; 6.8 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 103.6 &plusmn; 19.5 minutes; prolonged in renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (~96%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brown JJ, Kristy RM, Stevens GR, et al, &ldquo;The OptiMARK Clinical Development Program: Summary of Safety Data,&rdquo;",
"      <i>",
"       J Magn Reson Imaging",
"      </i>",
"      , 2002, 15(4):446-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/55/25461/abstract-text/11948834/pubmed\" id=\"11948834\" target=\"_blank\">",
"        11948834",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control, &ldquo;Nephrogenic Fibrosing Dermopathy Associated with Exposure to Gadolinium-Containing Contrast Agents: St. Louis, Missouri,&rdquo;",
"      <i>",
"       MMWR Weekly Rep,",
"      </i>",
"      2007, 56(07):137-141.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Emerson J and Kost G, &ldquo;Spurious Hypocalcemia After Omniscan- or Optimark-Enhanced Magnetic Resonance Imaging: An Algorithm for Minimizing a False-Positive Laboratory Value,&rdquo;",
"      <i>",
"       Arch Pathol Lab Med",
"      </i>",
"      , 2004, 128(10):1151-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/55/25461/abstract-text/15387706/pubmed\" id=\"15387706\" target=\"_blank\">",
"        15387706",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Expert Panel on MR Safety, \"ACR Guidance Document on MR Safe Practices: 2013,\"",
"      <i>",
"       J Magn Reson Imaging",
"      </i>",
"      , 2013, 37(3):501-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/55/25461/abstract-text/23345200/pubmed\" id=\"23345200\" target=\"_blank\">",
"        23345200",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grobner T, &ldquo;Gadolinium - A Specific Trigger for the Development of Nephrogenic Fibrosing Dermopathy and Nephrogenic Systemic Fibrosis,&rdquo;",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 2006, 21(4):1104-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/55/25461/abstract-text/16431890/pubmed\" id=\"16431890\" target=\"_blank\">",
"        16431890",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Joffe P, Thomsen HS, and Meusel M, \"Pharmacokinetics of Gadodiamide Injection in Patients with Severe Renal Insufficiency and Patients Undergoing Hemodialysis or Continuous Ambulatory Peritoneal Dialysis,\"",
"      <i>",
"       Acad Radiol",
"      </i>",
"      , 1998, 5(7):491-502.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/55/25461/abstract-text/9653466/pubmed\" id=\"9653466\" target=\"_blank\">",
"        9653466",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kuo PH, Kanal E, Abu-Alfa AK, et al, \"Gadolinium-Based MR Contrast Agents and Nephrogenic Systemic Fibrosis,\"",
"      <i>",
"       Radiology",
"      </i>",
"      , 2007, 242(3):647-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/55/25461/abstract-text/17213364/pubmed\" id=\"17213364\" target=\"_blank\">",
"        17213364",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Okada S, Katagiri K, Kumazaki T, et al, &ldquo;Safety of Gadolinium Contrast Agent in Hemodialysis Patients,&rdquo;",
"      <i>",
"       Acta Radiol",
"      </i>",
"      , 2001, 42(3):339-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/55/25461/abstract-text/11350296/pubmed\" id=\"11350296\" target=\"_blank\">",
"        11350296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tremblay E, Th&eacute;rasse E, Thomassin-Naggara I, et al, \"Quality Initiatives: Guidelines for Use of Medical Imaging During Pregnancy and Lactation,\"",
"      <i>",
"       Radiographics",
"      </i>",
"      , 2012, 32(3):897-911.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/55/25461/abstract-text/22403117/pubmed\" id=\"22403117\" target=\"_blank\">",
"        22403117",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang PI, Chong ST, Kielar AZ, et al, \"Imaging of Pregnant and Lactating Patients: Part 1, Evidence-Based Review and Recommendations,\"",
"      <i>",
"       AJR Am J Roentgenol",
"      </i>",
"      , 2012, 198(4):778-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/55/25461/abstract-text/22451541/pubmed\" id=\"22451541\" target=\"_blank\">",
"        22451541",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wanko SO, Telen MJ, &ldquo;Transfusion Management in Sickle Cell Disease,&rdquo;",
"      <i>",
"       Hematol Oncol Clin N Am",
"      </i>",
"      , 2005, 19(5):803-26.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Webb JA, Thomsen HS, and Morcos SK, \"The Use of Iodinated and Gadolinium Contrast Media During Pregnancy and Lactation,\"",
"      <i>",
"       Eur Radiol",
"      </i>",
"      , 2005, 15(6):1234-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/55/25461/abstract-text/15609057/pubmed\" id=\"15609057\" target=\"_blank\">",
"        15609057",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Widmark JM, &ldquo;Imaging-related Medications: A Class Overview,&rdquo;",
"      <i>",
"       Proc(Bayl Univ Med Cent)",
"      </i>",
"      , 2007, 20(4):408-17.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8965 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-84581B2B62-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_55_25461=[""].join("\n");
var outline_f24_55_25461=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708887\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3414728\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15572566\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3414732\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3414760\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3414761\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3414762\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3414763\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3414767\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3414730\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3414764\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3414733\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12932490\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174544\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3414743\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415128\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3414739\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299381\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5562963\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3414734\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3414735\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3414737\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3414738\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322955\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3950496\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038889\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3414753\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3414755\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8965\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8965|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/38/33379?source=related_link\">",
"      Gadoversetamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_55_25462="Bland alveolar hemorrhage DAH";
var content_f24_55_25462=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bland pulmonary hemorrhage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 245px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of bland pulmonary hemorrhage in which the alveolar spaces are filled with red blood cells. The alveolar septa appear normal except for type II epithelial lining cell hyperplasia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marvin I Schwarz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_55_25462=[""].join("\n");
var outline_f24_55_25462=null;
var title_f24_55_25463="Childhood immunization schedule 0 to 6 yrs";
var content_f24_55_25463=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 676px\">",
"   <div class=\"ttl\">",
"    Recommended immunization schedule for persons aged 0 through 6 years - United States, 2013 (for those who fall behind or start late, see the catch-up schedule)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 656px; height: 816px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This schedule includes recommendations in effect as of January 1, 2013. Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible. The use of a combination vaccine generally is preferred over separate injections of its equivalent component vaccines. Vaccination providers should consult the relevant Advisory Committee on Immunization Practices (ACIP) statement for detailed recommendations, available online at",
"    <a href=\"file://www.cdc.gov/vaccines/pubs/acip-list.htm\" target=\"_blank\">",
"     www.cdc.gov/vaccines/pubs/acip-list.htm",
"    </a>",
"    . Clinically significant adverse events that follow vaccination should be reported to the Vaccine Adverse Event Reporting System (VAERS) at",
"    <a href=\"file://www.vaers.hhs.gov\" target=\"_blank\">",
"     www.vaers.hhs.gov",
"    </a>",
"    or by telephone, 800-822-7967. Suspected cases of vaccine-preventable diseases should be reported to the state or local health department. Additional information including precautions and contraindications for vaccination is available from the CDC online at",
"    <a href=\"file://www.cdc.gov/vaccines\" target=\"_blank\">",
"     www.cdc.gov/vaccines",
"    </a>",
"    or by telephone, 800-232-4636. This schedule is approved by the ACIP, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American College of Obstetricians and Gynecologists.",
"    <div class=\"footnotes\">",
"     *",
"     <strong>",
"      Hepatitis B (HepB) vaccine:",
"     </strong>",
"     <em>",
"      (Minimum age: birth)",
"     </em>",
"     <br>",
"      -",
"      <strong>",
"       At birth:",
"      </strong>",
"      : Administer monovalent HepB vaccine to all newborns before hospital discharge. For infants born to hepatitis B surface antigen (HBsAg)-positive mothers, administer HepB vaccine and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours of birth. These infants should be tested for HBsAg and antibody to HBsAg (anti-HBs) 1 to 2 months after completion of the HepB series, at age 9 through 18 months (preferably at the next well-child visit). If mother's HBsAg status is unknown, within 12 hours of birth administer HepB vaccine to all infants regardless of birth weight. For infants weighing &lt;2000 grams, administer HBIG in addition to HepB within 12 hours of birth. Determine mother's HBsAg status as soon as possible and, if she is HBsAg-positive, also administer HBIG for infants weighing &ge;2000 grams (no later than age 1 week).",
"      <br>",
"       -",
"       <strong>",
"        Doses following the birth dose:",
"       </strong>",
"       The second dose should be administered at age 1 or 2 months. Monovalent HepB vaccine should be used for doses administered before age 6 weeks. Infants who did not receive a birth dose should receive 3 doses of a HepB-containing vaccine on a schedule of 0, 1 to 2 months, and 6 months starting as soon as feasible. The minimum interval between dose 1 and dose 2 is 4 weeks and between dose 2 and 3 is 8 weeks. The final (third or fourth) dose in the HepB vaccine series should be administered no earlier than age 24 weeks, and at least 16 weeks after the first dose. Administration of a total of 4 doses of HepB vaccine is recommended when a combination vaccine containing HepB is administered after the birth dose.",
"       <br>",
"        <font class=\"bullet\">",
"         &bull;",
"        </font>",
"        <strong>",
"         Rotavirus (RV) vaccine:",
"        </strong>",
"        <em>",
"         (Minimum age: 6 weeks for both RV1 [Rotarix] and RV5 [RotaTeq])",
"        </em>",
"        Administer a series of RV vaccine to all infants as follows: 1) If RV1 is used, administer a 2-dose series at 2 and 4 months of age. 2) If RV5 is used, administer a 3-dose series at ages 2, 4, and 6 months. 3) If any dose in series was RV5 or vaccine product is unknown for any dose in the series, a total of 3 doses of RV vaccine should be administered.",
"        <br>",
"         &Delta;",
"         <strong>",
"          Diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine:",
"         </strong>",
"         <em>",
"          (Minimum age: 6 weeks)",
"         </em>",
"         Administer a 5-dose series of DTaP vaccine at ages 2, 4, 6, 15 to 18 months, and 4 through 6 years. The fourth dose may be administered as early as age 12 months, provided at least 6 months have elapsed since the third dose.",
"         <br>",
"          <font class=\"lozenge\">",
"           &loz;",
"          </font>",
"          <strong>",
"           <em>",
"            Haemophilus influenzae",
"           </em>",
"           type b (Hib) conjugate vaccine:",
"          </strong>",
"          <em>",
"           (Minimum age: 6 weeks)",
"          </em>",
"          Administer a Hib vaccine primary series and a booster dose to all infants. The primary series doses should be administered at 2, 4, and 6 months of age; however, if PRP-OMP (PedvaxHib or Comvax) is administered at 2 and 4 months of age, a dose at age 6 months is not indicated. One booster dose should be administered at age 12 through 15 months. Hiberix (PRP-T) should only be used for the booster (final) dose in children aged 12 months through 4 years, who have received at least 1 dose of Hib.",
"          <br>",
"           <strong>",
"            Vaccination of persons with high-risk conditions:",
"           </strong>",
"           Hib vaccine is not routinely recommended for patients older than 5 years of age. However 1dose of Hib vaccine should be administered to unvaccinated or partially vaccinated persons aged 5 years or older who have leukemia, malignant neoplasms, anatomic or functional asplenia (including sickle cell disease), human immunodeficiency virus (HIV) infection, or other immunocompromising conditions.",
"           <br>",
"            &sect;",
"            <strong>",
"             Pneumococcal conjugate vaccine (PCV):",
"            </strong>",
"            <em>",
"             (Minimum age: 6 weeks)",
"            </em>",
"            Administer a series of PCV13 vaccine at ages 2, 4, 6 months with a booster at age 12 through 15 months. For children aged 14 through 59 months who have received an age-appropriate series of 7-valent PCV (PCV7), administer a single supplemental dose of 13-valent PCV (PCV13).",
"            <br>",
"             <strong>",
"              Vaccination of persons with high-risk conditions:",
"             </strong>",
"             For children aged 24 through 71 months with high risk conditions (listed below), administer 1 dose of PCV13 if 3 doses of PCV were received previously, or administer 2 doses of PCV13 at least 8 weeks apart if fewer than 3 doses of PCV were received previously. Children with high risk conditions aged 2 years or older also should receive pneumococcal polysaccharide vaccine (PPSV23) at least 8 weeks after the last dose of PCV. A single dose of PCV13 may be administered to previously unvaccinated children aged 6 through 18 years who have anatomic or functional asplenia (including sickle cell disease), HIV infection or an immunocompromising condition, cochlear implant or cerebrospinal fluid leak. See MMWR 2010; 59 (No. RR-11), available at",
"             <a href=\"file://www.cdc.gov/mmwr/pdf/rr/rr5911.pdf\" target=\"_blank\">",
"              www.cdc.gov/mmwr/pdf/rr/rr5911.pdf",
"             </a>",
"             .",
"             <br>",
"              <strong>",
"               High risk conditions:",
"              </strong>",
"              1) Immunocompetent children with chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure); chronic lung disease (including asthma if treated with high-dose oral corticosteroid therapy), diabetes mellitus; cerebrospinal fluid leaks; or cochlear implant. 2) Children with anatomic or functional asplenia (including sickle cell disease and other hemoglobinopathies, congenital or acquired asplenia, or splenic dysfunction). 3) Children with immunocompromising conditions: HIV infection, chronic renal failure and nephrotic syndrome, diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas and Hodgkin disease; or solid organ transplantation, congenital immunodeficiency.",
"              <br>",
"               &yen;",
"               <strong>",
"                Pneumococcal polysaccharide vaccine (PPSV23):",
"               </strong>",
"               <em>",
"                (Minimum age: 2 years)",
"               </em>",
"               Administer PPSV23 at least 8 weeks after the last dose of PCV to children aged 2 years or older with high risk conditions (listed above). A single revaccination with PPSV23 should be administered after 5 years to children with anatomic or functional asplenia (including sickle cell disease) or an immunocompromising condition.",
"               <br>",
"                &Dagger;",
"                <strong>",
"                 Inactivated poliovirus (IPV) vaccine:",
"                </strong>",
"                <em>",
"                 (Minimum age: 6 weeks)",
"                </em>",
"                Administer a series of IPV at ages 2, 4, 6 to 18 months, with a booster at age 4 to 6 years. The final dose in the series should be administered on or after the fourth birthday and at least 6 months after the previous dose.",
"                <br>",
"                 &dagger;",
"                 <strong>",
"                  Influenza vaccine:",
"                 </strong>",
"                 <em>",
"                  (Minimum age: 6 months for inactivated influenza vaccine [IIV]; 2 years for live, attenuated influenza vaccine [LAIV])",
"                 </em>",
"                 Administer influenza vaccine annually to all children beginning at age 6 months. For most healthy, nonpregnant persons aged 2 through 49 years, either LAIV or IIV may be used. However, LAIV should NOT be administered to some persons, including 1) those with asthma, 2) children 2 through 4 years who had wheezing in the past 12 months, or 3) those who have any other underlying medical conditions that predispose them to influenza complications. For all other contraindications to use of LAIV see MMWR 2010; 59 (No. RR-8), available at",
"                 <a href=\"file://www.cdc.gov/mmwr/pdf/rr/rr5908.pdf\" target=\"_blank\">",
"                  www.cdc.gov/mmwr/pdf/rr/rr5908.pdf",
"                 </a>",
"                 . Administer 1 dose to persons aged 9 years and older. For children aged 6 months through 8 years: For the 2012-13 season, administer 2 doses (separated by at least 4 weeks) to children who are receiving influenza vaccine for the first time. For additional guidance, follow dosing guidelines in the 2012 ACIP influenza vaccine recommendations, MMWR 2012; 61:613, available at",
"                 <a href=\"file://www.cdc.gov/mmwr/pdf/wk/mm6132.pdf\" target=\"_blank\">",
"                  www.cdc.gov/mmwr/pdf/wk/mm6132.pdf",
"                 </a>",
"                 . For the 2013-14 season, follow dosing guidelines in the 2013 ACIP influenza vaccine recommendations.",
"                 <br>",
"                  **",
"                  <strong>",
"                   Measles, mumps, and rubella (MMR) vaccine:",
"                  </strong>",
"                  <em>",
"                   (Minimum age: 12 months)",
"                  </em>",
"                  Administer the first dose of MMR vaccine at age 12 through 15 months, and the second dose at age 4 through 6 years. The second dose may be administered before age 4 years, provided at least 4 weeks have elapsed since the first dose. Administer 1 dose of MMR vaccine to infants aged 6 through 11 months before departure from the United States for international travel. These children should be revaccinated with 2 doses of MMR vaccine, the first at age 12 through 15 months (12 months if the child remains in an area where disease risk is high), and the second dose at least 4 weeks later. Administer 2 doses of MMR vaccine to children aged 12 months and older, before departure from the United States for international travel. The first dose should be administered on or after age 12 months and the second dose at least 4 weeks later.",
"                  <br>",
"                   <font class=\"double_bullet\">",
"                    &bull;&bull;",
"                   </font>",
"                   <strong>",
"                    Varicella (VAR) vaccine:",
"                   </strong>",
"                   <em>",
"                    (Minimum age: 12 months)",
"                   </em>",
"                   Administer the first dose of VAR vaccine at age 12 through 15 months, and the second dose at age 4 through 6 years. The second dose may be administered before age 4 years, provided at least 3 months have elapsed since the first dose. If the second dose was administered at least 4 weeks after the first dose, it can be accepted as valid.",
"                   <br>",
"                    &Delta;&Delta;",
"                    <strong>",
"                     Hepatitis A (Hep A) vaccine:",
"                    </strong>",
"                    <em>",
"                     (Minimum age: 12 months)",
"                    </em>",
"                    Initiate the 2-dose HepA vaccine series for children aged 12 through 23 months; separate the 2 doses by 6 to 18 months. Children who have received 1 dose of HepA vaccine before age 24 months should receive a second dose 6 to 18 months after the first dose. For any person aged 2 years and older who has not already received the HepA vaccine series, 2 doses of HepA vaccine separated by 6 to 18 months may be administered if immunity against hepatitis A virus infection is desired.",
"                    <strong>",
"                     Special populations:",
"                    </strong>",
"                    Administer 2 doses of HepA vaccine at least 6 months apart to previously unvaccinated persons who live in areas where vaccination programs target older children, or who are at increased risk for infection.",
"                    <br>",
"                     <font class=\"double_lozenge\">",
"                      &loz;&loz;",
"                     </font>",
"                     <strong>",
"                      Meningococcal conjugate vaccines (MCV):",
"                     </strong>",
"                     <em>",
"                      (Minimum age: 6 weeks for (Menhibrix) HibMenCY, 9 months for Menactra [MCV4-D], 2 years for Menveo [MCV4-CRM])",
"                     </em>",
"                     Vaccination of persons with high-risk conditions: For children younger than 19 months of age with anatomic or functional asplenia (including sickle cell disease), administer an infant series of HibMenCY at 2, 4, 6, and 12 to 15 months. For children aged 2 through 18 months with persistent complement component deficiency, administer either an infant series of HibMenCY at 2, 4, 6, and 12 through 15 months or a 2-dose primary series of MCV4-D starting at 9 months, with at least 8 weeks between doses. For children aged 19 through 23 months with persistent complement component deficiency who have not received a complete series of HibMenCY or MCV4-D, administer 2 primary doses of MCV4-D at least 8 weeks apart. For children aged 24 months and older with persistent complement component deficiency or anatomic or functional asplenia (including sickle cell disease), who have not received a complete series of HibMenCY or MCV4-D, administer 2 primary doses of either MCV4-D or MCV4-CRM. MCV4-D should not be administered to a child with asplenia (including sickle cell disease) until 2 years of age and at least 4 weeks after the completion of all PCV13 doses. See MMWR 2011; 60:1391, available at",
"                     <a href=\"file://www.cdc.gov/mmwr/pdf/wk/mm6040.pdf\" target=\"_blank\">",
"                      www.cdc.gov/mmwr/pdf/wk/mm6040.pdf",
"                     </a>",
"                     . For children aged 9 months and older who are residents of or travelers to countries in the African meningitis belt or to the Hajj, administer an age-appropriate formulation and series of MCV4 for protection against serogroups A and W-135. Prior receipt of HibMenCY is not sufficient for children traveling to the meningitis belt or the Hajj. See MMWR 2011; 60:1391, available at",
"                     <a href=\"file://www.cdc.gov/mmwr/pdf/wk/mm6040.pdf\" target=\"_blank\">",
"                      www.cdc.gov/mmwr/pdf/wk/mm6040.pdf",
"                     </a>",
"                     . For children who are present during outbreaks caused by a vaccine serogroup, administer or complete an age- and formulation-appropriate series of HibMenCY or MCV4. For booster doses among persons with high-risk conditions refer to",
"                     <a href=\"file://www.cdc.gov/vaccines/pubs/acip-list.htm#mening\" target=\"_blank\">",
"                      www.cdc.gov/vaccines/pubs/acip-list.htm#mening",
"                     </a>",
"                     .",
"                    </br>",
"                   </br>",
"                  </br>",
"                 </br>",
"                </br>",
"               </br>",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Akinsanya-Beysolow I, Jenkins R, Meissner HC, Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC. Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Persons Aged 0 Through 18 Years - United States, 2013. MMWR Surveill Summ 2013; 62:2. Available at:",
"     <a href=\"file://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-schedule.pdf\" target=\"_blank\">",
"      www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-schedule.pdf",
"     </a>",
"     (Accessed on February 3, 2013).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_55_25463=[""].join("\n");
var outline_f24_55_25463=null;
var title_f24_55_25464="12 lead ECG antidromic AVRT";
var content_f24_55_25464=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1208px;\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    12-lead electrocardiogram (ECG) showing antidromic atrioventricular reentrant tachycardia (AVRT) in a patient with an accessory AV pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 350px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 12 lead ECG of a patient with Wolff-Parkinson-White shows a regular tachycardia. The QRS complexes are widened and are identical to the QRS complexes seen in sinus rhythm; the antegrade conduction to the ventricle is via the accessory pathway and retrograde conduction is via the normal His-atrioventicular node pathway. This is therefore an antidromic atrioventricular reentant tachycardia or AAVRT.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martin Burke, DO.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    ECG in Wolff-Parkinson-White",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 365px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 12 lead ECG shows the typical features of Wolff-Parkinson-White; the PR interval is short (*) and the QRS duration prolonged as a result of a delta wave (arrow), indicating ventricular preexcitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martin Burke, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_55_25464=[""].join("\n");
var outline_f24_55_25464=null;
var title_f24_55_25465="Heart failure self management";
var content_f24_55_25465=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Heart failure self management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/55/25465/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/55/25465/contributors\">",
"     Leora Horwitz, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/55/25465/contributors\">",
"     Harlan Krumholz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/55/25465/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/55/25465/contributors\">",
"     Sharon A Hunt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/55/25465/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/55/25465/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/55/25465/contributors\">",
"     Constanza Villalba, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/55/25465/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6599888\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure (HF) is one of the most common causes of hospitalization, hospital readmission, and death. Due to the complexity and long-term nature of HF regimens, the need for careful diet and weight management, and the importance of intervention in the early phases of decompensation, patient self management is crucial in avoiding hospitalizations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/1\">",
"     1",
"    </a>",
"    ]. Unfortunately, many patients lack self-care skills [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    This topic will review evidence for the value of self management and strategies for educating patients about self management of HF. The medical management of HF and treatment for acute decompensation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33446?source=see_link\">",
"     \"Treatment of acute decompensated heart failure in acute coronary syndromes\"",
"    </a>",
"    .) Strategies for avoiding hospitalization are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37929?source=see_link\">",
"     \"Strategies to reduce hospitalizations in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6599895\">",
"    <span class=\"h1\">",
"     MAGNITUDE OF THE PROBLEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 5.8 million Americans are living with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/4\">",
"     4",
"    </a>",
"    ]. In 2006, the HF hospitalization rate was 22.9 per 1,000 for men over age 64 and 19.6 per 1000 for women over age 64 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/5\">",
"     5",
"    </a>",
"    ], making HF the leading cause of hospitalization in this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/6\">",
"     6",
"    </a>",
"    ]. Furthermore, 27 percent of those who are hospitalized once with HF are typically readmitted within 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic HF care requires patients to follow complex medical regimens, comply with diet and exercise recommendations, actively engage with clinicians, and modify medications and behavior according to symptoms. This &ldquo;self care&rdquo; is quite complex. Standard HF medical regimens often include at minimum three distinct classes of medications, some of which may be taken multiple times a day. In addition, patients are expected to restrict salt intake, monitor their weight daily, be able to identify early warning signs of deterioration, and adjust diuretic use according to clinical changes. Patients and caregivers may find these activities difficult to perform without education and support.",
"   </p>",
"   <p>",
"    The consequences of inadequate self care are profound. Inability to manage medications or diet may account for as many as one in five admissions for HF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/7\">",
"     7",
"    </a>",
"    ]. Conversely, improved self-management skills may reduce the odds of readmission at one year by 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, assisting patients to manage their own care is an essential component of chronic HF management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6599902\">",
"    <span class=\"h1\">",
"     BENEFIT OF SELF-MANAGEMENT INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies of self-management intervention in patients with heart failure have been multifaceted disease-management interventions that included interventions in addition to self-management education and promotion. Consequently, it is difficult to distinguish effects of self-management from other components of these complex interventions. They are also context dependent, and it is not clear how generalizable they are.",
"   </p>",
"   <p>",
"    In general, trials of long-term self-care education with frequent reinforcement have produced significant decreases in hospitalizations but no reduction in mortality. The results of some of the larger trials and meta-analyses of smaller trials of self-management and other disease management strategies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37929?source=see_link&amp;anchor=H18202439#H18202439\">",
"     \"Strategies to reduce hospitalizations in patients with heart failure\", section on 'Evidence of effectiveness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6599930\">",
"    <span class=\"h1\">",
"     WHAT CONSTITUTES APPROPRIATE SELF CARE?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Self care for heart failure encompasses a spectrum of behaviors ranging from adherence to medication, exercise and diet recommendations (self-care maintenance), to recognition of early warning signs, and self adjustment of the home-care regimen (self-care management). Two tools to assess patients&rsquo; self-care abilities have been validated: the Self Care of Heart Failure Index [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/8\">",
"     8",
"    </a>",
"    ] and the European Heart Failure Self-care Behavior Scale (available in multiple languages) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/9\">",
"     9",
"    </a>",
"    ]. However, at present neither is commonly used outside the research setting.",
"   </p>",
"   <p>",
"    For patients with heart failure, the chief components of self care programs are: medication management, daily monitoring for",
"    <span class=\"nowrap\">",
"     signs/symptoms,",
"    </span>",
"    and adherence to a low sodium diet and routine exercise. These are discussed in detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6599937\">",
"    <span class=\"h2\">",
"     Medication management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trial data show that treatment with beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/10-13\">",
"     10-13",
"    </a>",
"    ], angiotensin converting enzyme inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/14,15\">",
"     14,15",
"    </a>",
"    ],",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angiotensin II receptor blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/16,17\">",
"     16,17",
"    </a>",
"    ] reduces hospitalization and mortality rates in patients with heart failure. However, for medications to be effective for prolonged periods outside the clinical trial setting, patients must have adequate medication-management skills. For example, in a randomized trial of 314 low-income patients with heart failure, half of whom were given intensive education by a pharmacist about medication management, the intervention group had higher adherence (78.8 percent) than the control group (67.9 percent) and subsequently required fewer emergency and hospital visits (incidence rate ratio, 0.82 [CI, 0.73 to 0.93]). Consequently, medication management is considered to be a cardinal self-care behavior. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Self care for medication management includes a wide variety of skills and practices:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtaining initial and refill prescriptions",
"     </li>",
"     <li>",
"      Incorporating medication administration into the daily routine",
"     </li>",
"     <li>",
"      Adhering to the daily medication schedule",
"     </li>",
"     <li>",
"      Understanding and implementing prescription changes",
"     </li>",
"     <li>",
"      Recognizing common side effects of medications, and",
"     </li>",
"     <li>",
"      Managing changes of routine such as travel or acute illness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Self-care programs teach each of these skills, utilizing written, oral, graphic, video",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    electronic tools. An example of a medication maintenance schedule geared for low-literacy patients is the discharge instruction packet developed at Boston University [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/18\">",
"     18",
"    </a>",
"    ]. Other graphic aids to improve medication adherence have been developed at Emory University [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/19\">",
"     19",
"    </a>",
"    ], University of California, Los Angeles [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/20\">",
"     20",
"    </a>",
"    ] and elsewhere. A medication management tool to help low-literacy patients adjust medications based on weight has been developed at University of North Carolina [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/21\">",
"     21",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_figure graphicRef73970 \" href=\"UTD.htm?1/52/1864\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6599953\">",
"    <span class=\"h3\">",
"     Patient medication instructions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To take each medication each day at the times indicated by using a system (list, pill box, etc.)",
"     </li>",
"     <li>",
"      Not to allow prescriptions to expire or bottles to become empty before refilling",
"     </li>",
"     <li>",
"      To use the same pharmacy each time",
"     </li>",
"     <li>",
"      Not to skip doses, even when they are feeling well",
"     </li>",
"     <li>",
"      To bring all their medications to each doctor&rsquo;s visit",
"     </li>",
"     <li>",
"      To contact their doctor immediately if they feel they are having side effects from medications, rather than stopping them without telling anyone",
"     </li>",
"     <li>",
"      To discuss barriers to obtaining medications (such as cost difficulties) with the physician",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6599961\">",
"    <span class=\"h3\">",
"     Instructions for patients able to perform medication management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Which pill is their diuretic",
"     </li>",
"     <li>",
"      How to change the dose of the diuretic according to the HF action plan",
"     </li>",
"     <li>",
"      To carry out any additional changes that should accompany diuretic dosage changes (ie, need for earlier refills, addition of potassium supplementation)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who have been properly instructed to perform medication management should be able to demonstrate the ability to carry out these activities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6599971\">",
"    <span class=\"h2\">",
"     Daily monitoring of signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain signs and symptoms often precede the need for further changes in clinical status that ultimately require hospitalization. For example, in a nested case-control study of 134 patients hospitalized for heart failure exacerbation and 134 similar patients who were not hospitalized, the relative odds ratio of hospitalization was 2.8 (95% CI 1.1 to 6.8) for a weight gain of &gt;2 to 5 pounds versus two pounds or fewer in one week. For patients who gained &gt;5 to 10 pounds in a week the odds of hospitalization were 4.5 times those who gained two pounds or fewer (95% CI 1.5 to 13.8), and for those who gained more than 10 pounds, the relative odds were 7.6 (95% CI 2.2 to 26.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/22\">",
"     22",
"    </a>",
"    ]. Consequently, early identification of worsening clinical status through symptom monitoring may be helpful in avoiding hospitalization. Of note, studies about exactly how this ought to be done, and the magnitude of the expected effect, are still lacking. &nbsp;",
"   </p>",
"   <p>",
"    Self-care programs typically include the following suggestions for monitoring of signs and symptoms:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6599979\">",
"    <span class=\"h3\">",
"     Daily weights",
"    </span>",
"   </p>",
"   <p>",
"    Patients should be instructed to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use a scale with large enough print to be readily visible",
"     </li>",
"     <li>",
"      Use a scale that is big enough for the patient to stand on easily",
"     </li>",
"     <li>",
"      Use a scale that is easy to &ldquo;zero,&rdquo; such as a digital scale",
"     </li>",
"     <li>",
"      Weigh themselves at the same time every morning",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      After urinating but before eating or drinking",
"     </li>",
"     <li>",
"      Before getting dressed or in the same amount of clothing each day",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Record the results in a log book or other permanent record",
"     </li>",
"     <li>",
"      Compare results to previous day and to previous week",
"     </li>",
"     <li>",
"      Know their target weight",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A reasonable plan might be that for a two to five pound weight gain in one week,",
"    <span class=\"nowrap\">",
"     diet/medication",
"    </span>",
"    changes should be made as outlined in HF action plan; &gt;5 pound weight gain in one week requires immediate call to the designated physician or nurse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6599987\">",
"    <span class=\"h3\">",
"     Daily check for edema",
"    </span>",
"   </p>",
"   <p>",
"    Patients should be instructed to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Examine their legs each day for swelling or an increase in existing swelling",
"     </li>",
"     <li>",
"      Describe how far up the leg the swelling reaches (ankle, shin, knee)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Worsening edema requires",
"    <span class=\"nowrap\">",
"     diet/medication",
"    </span>",
"    changes as outlined on the HF action plan; severe swelling requires immediate call to the designated physician or nurse. It is not necessary to teach patients the classic edema scale (1+ to 4+ pitting), as even clinicians are unreliable in assigning scores to edema [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measuring ankle circumference with a soft tape measure is a more reliable objective measure that is easy to teach patients if a quantitative measure is desired [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/23\">",
"     23",
"    </a>",
"    ]. However, there are no data to show this is more effective than a subjective assessment of &ldquo;worsening.&rdquo;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6599995\">",
"    <span class=\"h3\">",
"     Daily check of symptom severity",
"    </span>",
"   </p>",
"   <p>",
"    Patients should perform the following checks daily:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monitor their exercise tolerance (eg, using a scale ranging from no shortness of breath, shortness of breath after moderate exertion, shortness of breath after mild exertion, shortness of breath at rest)",
"     </li>",
"     <li>",
"      Monitor their breathing at night (eg, using a scale ranging from no shortness of breath lying flat, needing two pillows or more, sleeping upright or awakening with sudden shortness of breath)",
"     </li>",
"     <li>",
"      Watch for dizziness or lightheadedness (eg, using a scale ranging from not dizzy, dizzy for a while after standing, near",
"      <span class=\"nowrap\">",
"       syncope/syncope",
"      </span>",
"      or fall)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For each of these symptoms, patients should be instructed that the less-severe symptoms would require",
"    <span class=\"nowrap\">",
"     diet/medication",
"    </span>",
"    modification as outlined in the HF action plan and the more severe symptoms would require an immediate call to the physician&rsquo;s office. (See",
"    <a class=\"local\" href=\"#H6600128\">",
"     'Heart failure action plan'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6600002\">",
"    <span class=\"h2\">",
"     Adherence to sodium restricted diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clinical trials demonstrating a benefit of a low-sodium (2g) diet in heart failure. Studies of patients hospitalized with acute exacerbations of HF have found excess dietary sodium to be a precipitating event in approximately one-fifth of patients; however, these studies did not include control groups of nonhospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. A recent study of a low-sodium (2g) diet compared with a 3g sodium diet in patients also on high-dose oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    and 1L fluid restriction actually found harm from a low-sodium diet: 7.6 percent readmission rate after 180 days on 3g sodium diet versus 26.3 percent on 2g sodium diet [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/27\">",
"     27",
"    </a>",
"    ]. However, this study has been criticized for its unusually high dose of furosemide (250 to 500mg bid) that was not altered even on the low-sodium diet.",
"   </p>",
"   <p>",
"    On the other hand, sodium restriction can reduce blood pressure in normotensive and hypertensive individuals and can enhance the response to antihypertensive drugs, except possibly calcium channel blockers. Sodium restriction may also diminish the potassium wasting in patients treated with diuretics and have other cardiovascular benefits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24120?source=see_link&amp;anchor=H10#H10\">",
"     \"Salt intake, salt restriction, and essential hypertension\", section on 'Effects of dietary sodium restriction on blood pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Consequently, dietary sodium restriction remains a recommended component of cardiac self management. A sodium-restricted diet for patients with edema is recommended by all major societies including the 2010 Heart Failure Society of America (HFSA) guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/28\">",
"     28",
"    </a>",
"    ], and the 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    heart failure guidelines (with 2009 focused update) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adherence to a low-sodium diet requires the following knowledge and skills:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Understanding of relationship between sodium intake and edema",
"     </li>",
"     <li>",
"      Knowledge that sodium and &ldquo;salt&rdquo; are the same",
"     </li>",
"     <li>",
"      Ability to read a nutrition label",
"     </li>",
"     <li>",
"      Ability to calculate total sodium intake in a day",
"     </li>",
"     <li>",
"      Recognition of &ldquo;hidden&rdquo; sources of salt intake (ie,",
"      <span class=\"nowrap\">",
"       sauces/seasonings,",
"      </span>",
"      canned goods, instant hot cereals)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Self-care programs teach each of these skills, utilizing written, oral, graphic, video",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    electronic tools. For example, the North Carolina Program on Health Literacy has developed a low-literacy-appropriate",
"    <a class=\"external\" href=\"file://www.nchealthliteracy.org/hfselfmanage.html\">",
"     HF pamphlet",
"    </a>",
"    that provides these lessons in pictorial format [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to education about the knowledge and skills described above, patients should be instructed to perform the following actions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Select low-salt foods and avoid high-salt foods, including processed meats and hot cereals",
"     </li>",
"     <li>",
"      Reduce salt added during home cooking",
"     </li>",
"     <li>",
"      Ask for reduced-salt meals at restaurants and avoid known sources of salt",
"     </li>",
"     <li>",
"      Rinse canned goods before cooking",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      eating",
"     </li>",
"     <li>",
"      Avoid instant foods and salty snacks",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9750301\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no clinical trials demonstrating a morbidity or mortality benefit to routine exercise in heart failure. However, clinical studies suggest that exercise training is safe in appropriately screened patients with stable NYHA class II to class III HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) due to LV systolic dysfunction. As noted in the 2010 HFSA guidelines, patients with HF should undergo exercise testing to determine suitability (absence of significant ischemia or arrhythmias) prior to exercise training [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/28\">",
"     28",
"    </a>",
"    ]. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=see_link\">",
"     \"Cardiac rehabilitation in patients with heart failure\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6600009\">",
"    <span class=\"h2\">",
"     Smoking cessation and alcohol use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current smoking is an independent predictor of mortality in patients with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/31\">",
"     31",
"    </a>",
"    ]. In one study of 7599 patients with a broad spectrum of heart failure severity, the adjusted hazard ratio for death was 1.34 (95% CI, 1.18-1.53) for current smokers versus never smokers, comparable to the risk of class III heart failure or previous myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/31\">",
"     31",
"    </a>",
"    ]. Smoking cessation is therefore an important part of heart failure self care and should be encouraged in all patients with heart failure who are active smokers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .) The 2010 HFSA guidelines recommend smoking cessation for all patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2010 HFSA guidelines recommend that patients with HF be advised to limit alcohol consumption to &le;2 standard drinks per day in men or &le;1 standard drink per day in women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/28\">",
"     28",
"    </a>",
"    ]. (",
"    <a class=\"graphic graphic_figure graphicRef68118 \" href=\"UTD.htm?4/61/5079\">",
"     figure 2",
"    </a>",
"    )(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35672?source=see_link\">",
"     \"Alcoholic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=see_link&amp;anchor=H9#H9\">",
"     \"Cardiovascular benefits and risks of moderate alcohol consumption\", section on 'Heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20636816\">",
"    <span class=\"h1\">",
"     OBSERVED RATES OF ADHERENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Existing literature on adherence to self-care behaviors in heart failure patients is limited by inconsistent methods of defining and assessing adherence and study of limited populations in small trials. Nonetheless, it is clear that patients do not typically engage in adequate self care [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20636823\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Published nonadherence rates to heart failure medications range from 2 to 90 percent due to inconsistent and subjective assessments [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/32\">",
"     32",
"    </a>",
"    ]. The largest studies of heart failure medication adherence, which used reliable prescription refill data, show that on average patients have an adequate supply of a given medication at home 60 to 88 percent of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. Given the relatively short half-life of heart failure medications and the necessity for persistent adrenergic blocking, however, very high adherence rates are now thought to be necessary to achieve a clinically-significant reduction in adverse outcomes. One observational study found that 88 percent adherence or better was necessary for improved event-free survival [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/37\">",
"     37",
"    </a>",
"    ]. However, observational studies of adherence may be confounded by healthy adherer effects, in which adherers do better even if they are taking placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/38\">",
"     38",
"    </a>",
"    ]. The longer the duration of therapy, the lower the adherence rate in terms of on-time refills [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/39\">",
"     39",
"    </a>",
"    ]. Clinicians often fail to recognize when patients are not adhering to medications [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20636830\">",
"    <span class=\"h2\">",
"     Daily weights",
"    </span>",
"    &nbsp;&mdash;&nbsp;Published adherence to daily weight measurement in randomized trials ranges from 20 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/41\">",
"     41",
"    </a>",
"    ]. However, it is probably much lower in the general population. In one observational study of 202 patients recently discharged after heart failure exacerbation, only 14 percent reported weighing themselves daily [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20636837\">",
"    <span class=\"h2\">",
"     Symptom monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptom monitoring is among the least well-performed of heart failure self-care activities. In the study of 202 recently discharged heart failure patients, only 9 percent reported monitoring themselves for symptom changes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20636844\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Published estimates of patients who engage in no physical activity at all range from 9 to 53 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/41\">",
"     41",
"    </a>",
"    ]. Even in randomized trials, such as ACTION-HF, adherence was difficult to maintain over time. In that study, the intervention group engaged in a median of 50 minutes a week of exercise in the third year (relative to the training goal of 120 minutes a week) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20636851\">",
"    <span class=\"h2\">",
"     Sodium-restricted diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Published rates of adherence range from 20 to 71 percent, but most studies rely on patient reports, which may be inaccurate or exaggerated [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20637567\">",
"    <span class=\"h1\">",
"     BARRIERS TO SELF CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reasons for inadequate self care in the population at large as reflected by low adherence rates are multifactorial. In addition to lack of knowledge, skills or commitment, as outlined above, there are a variety of other barriers to self care. These include socioeconomic factors, patient factors, treatment factors, and healthcare system factors. Clinicians must be aware of these impediments to self-care in order to maximize their patients&rsquo; ability to manage their disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19111?source=see_link\">",
"     \"Compliance with lipid altering medications and recommended lifestyle changes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23828?source=see_link\">",
"     \"Patient adherence and the treatment of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20637574\">",
"    <span class=\"h2\">",
"     Socioeconomic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;To help reduce the impact of socioeconomic factors, clinicians should be aware of the costs of common medications, ask patients whether they can afford their medications, reduce the cost of medications (if possible), and make efforts to reduce the financial burden of self-care activities on their patients.",
"   </p>",
"   <p>",
"    Medication cost is a significant barrier to adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/32\">",
"     32",
"    </a>",
"    ]. Clinicians can help patients maintain adherence to medications by being sensitive to cost. The three classes of medications most commonly recommended for heart failure patients are all available in generic form; several in each class are also deeply discounted at major retailers. Commonly-associated medications such as statins are also available at these discounted rates.",
"   </p>",
"   <p>",
"    Financial barriers also play a role in behavioral change. Examples include lack of insurance coverage for pharmaceutical smoking-cessation aids; the expense of fresh fruits and vegetables compared with the low cost of sodium- and cholesterol-rich foods; and the inability of many patients to afford formal exercise programs or gym memberships. Many patients do not even own a scale.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20637581\">",
"    <span class=\"h2\">",
"     Therapy-related factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;To overcome therapy-related barriers, clinicians should specifically query and counsel patients about common adverse effects of heart failure medications, ensure patients understand the potential benefits they can expect from their medications, maximize once daily formulations, and attempt to minimize pill quantity.",
"   </p>",
"   <p>",
"    Side effects of medications are a major reason for noncompliance [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/32\">",
"     32",
"    </a>",
"    ]. This has traditionally been considered particularly problematic for heart failure because both beta blockers and diuretics have been perceived to have high rates of side effects that patients may be reluctant to discuss, including impotence, mood dysfunction and incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/43\">",
"     43",
"    </a>",
"    ]. However, a recent analysis of 15 RCTs involving over 25,000 patients suggests that beta blocker therapy was not associated with a significant absolute annual increase in risk of reported depressive symptoms (6 per 1000 patients; 95% CI, -7 to 19). Beta blocker treatment was associated with small increases in fatigue (18 per 1000 patients; 95% CI, 5-30) and sexual dysfunction (5 per 1000 patients; 95% CI, 2-8) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It may, therefore, be helpful for clinicians to specifically counsel patients about the low likelihood of these effects. Likewise, it may help to counsel patients that frequent urination is a sign that medications are working, and that the volume of urination is likely to level off once a stable state has been reached.",
"   </p>",
"   <p>",
"    More frequently dosed medications are less likely to be taken consistently; these formulations should be avoided whenever possible [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/32\">",
"     32",
"    </a>",
"    ]. The number of daily pills is inversely correlated with adherence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20637588\">",
"    <span class=\"h2\">",
"     Patient factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient factors play perhaps the greatest role in nonadherence to heart failure self care. To address patient factors, clinicians should screen patients for depression and low health literacy, should tailor treatment regimens for individuals with multiple morbidities, in addition to promoting appropriate knowledge, skills, and patient engagement as described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20637595\">",
"    <span class=\"h3\">",
"     Low health literacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/45\">",
"     45",
"    </a>",
"    ] and a 2004 report from the Institute of Medicine (IOM) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/46\">",
"     46",
"    </a>",
"    ] defined health literacy as follows: &ldquo;The degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions.&rdquo; Reading literacy is not synonymous with health literacy. For instance, while 71 percent of low-literacy patients in one study could read, &ldquo;Take two tablets by mouth twice daily,&rdquo; only 35 percent could correctly identify how many pills a day they would take [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of low health literacy on HF outcomes is illustrated by a retrospective study of 1547 patients with HF median of 1.2 years follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/48\">",
"     48",
"    </a>",
"    ]. Low health literacy was independently associated with higher mortality (unadjusted rate 17.6 versus 6.3 percent; adjusted HR 1.97 [95% CI, 1.3 to 2.97]) but not hospitalization (unadjusted rate, 30.5 vs 23.2 percent; adjusted HR 1.05 [95% CI, 0.8 to 1.37]).",
"   </p>",
"   <p>",
"    Low health literacy is a key component of adherence to behavioral changes as well as to medications: for example, the ability to recognize changes in weights and then appropriately self-adjust diuretic dosage or call the physician requires substantial health literacy. However, when self-care education is appropriately targeted to health literacy level, patients with low health literacy can achieve the same benefit from self-care as those with high health literacy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2010 consensus statement from the HFSA proposed five steps for health care providers to address low health literacy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Step 1: Recognize that health literacy is real and may compromise patient care.",
"     </li>",
"     <li>",
"      Step 2: Identify patients at risk for low health literacy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17609?source=see_link&amp;anchor=H7#H7\">",
"       \"Literacy and patient care\", section on 'Detecting low literacy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Step 3: Formally screen patients who are at risk: Several health literacy measurement tools exist to rapidly screen patients for low health literacy in the outpatient setting [",
"      <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/50\">",
"       50",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17609?source=see_link&amp;anchor=H7#H7\">",
"       \"Literacy and patient care\", section on 'Detecting low literacy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Step 4: Document health literacy levels and learning preferences in patient records.",
"     </li>",
"     <li>",
"      Step 5: Integrate strategies to facilitate to facilitate health understanding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17609?source=see_link&amp;anchor=H12#H12\">",
"       \"Literacy and patient care\", section on 'Suggestions for practice'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17609?source=see_link&amp;anchor=H19#H19\">",
"       \"Literacy and patient care\", section on 'Health literacy interventions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20637602\">",
"    <span class=\"h3\">",
"     Multimorbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with multiple chronic illnesses face additional physical, cognitive and functional challenges to effective self care. These patients are more likely to have multiple clinicians and receive confusing or conflicting recommendations. The average Medicare patient with HF sees 15 providers a year. Patients with HF have larger and more complex therapeutic, self-monitoring and behavioral requirements. The presence of one condition may complicate treatment for others &ndash; as, for instance,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in a patient with coronary artery disease, a history of gastrointestinal bleeding, and HF (for which the risks and benefits of aspirin are uncertain). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42039?source=see_link&amp;anchor=H6#H6\">",
"     \"Drugs that should be avoided or used with caution in patients with heart failure\", section on 'Aspirin'",
"    </a>",
"    .) Yet, evidence from clinical trials provides limited guidance for treatment of patient with multiple chronic conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20637609\">",
"    <span class=\"h3\">",
"     Depression and anxiety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression and anxiety are highly prevalent among heart failure patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. These comorbidities impair self-care ability through a variety of means, including effects on cognition, function, social support, motivation and engagement [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/53\">",
"     53",
"    </a>",
"    ]. Patients with depression and HF have higher rates of medication nonadherence [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/54\">",
"     54",
"    </a>",
"    ], hospitalization, and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/55\">",
"     55",
"    </a>",
"    ]. Brief screens for depression in the outpatient setting have been validated and can be readily used in the clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20637616\">",
"    <span class=\"h3\">",
"     Healthcare team/system factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A host of system-related factors makes self-care education challenging. Clinicians, especially in the outpatient setting, are often ill-equipped to provide self-care education, monitoring and reinforcement. They may lack the skills",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    time to provide such education. Ancillary resources, such as nurse educators, pharmacists, informational materials or registries to identify at-risk patients, may not be available. Commercial payers and Medicare rarely reimburse for counseling, follow-up and monitoring. Self-care education makes up only a tiny fraction of recommended quality metrics. Finally, clinicians must coordinate with an extraordinary range of other clinicians: The typical primary care provider is expected to coordinate with 229 other clinicians in 117 practices to manage",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    patient panel [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H90371077\">",
"    <span class=\"h1\">",
"     PROMOTING EFFECTIVE SELF-CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful self care requires a knowledgeable, engaged, and committed patient with supportive caregivers, family and friends, embedded in a healthcare system and environment that facilitates self management. In particular, efforts to promote effective self care should include a focus on three main areas: Knowledge, skills and behavior",
"    <span class=\"nowrap\">",
"     change/engagement.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6600023\">",
"    <span class=\"h2\">",
"     Knowledge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple",
"    studies have shown that patients with heart failure are unable to describe their medication regimen, do not recognize symptoms of worsening heart failure, do not know how much sodium they should be ingesting, and have a variety of misconceptions about heart failure etiology, prognosis and management [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/53,58\">",
"     53,58",
"    </a>",
"    ]. These knowledge deficits impair patients&rsquo; ability to engage in effective self care. Patient retention and understanding of factual content can be increased by using a few validated techniques for adult education [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/59\">",
"     59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Utilize teach-back techniques to ensure the patient understands the materials (that is, ask the patient to &ldquo;teach&rdquo; the educator the information",
"      <span class=\"nowrap\">",
"       he/she",
"      </span>",
"      has just received)",
"     </li>",
"     <li>",
"      Ask specific questions to ensure the patient understands the materials; do",
"      <strong>",
"       not",
"      </strong>",
"      just say, &ldquo;Do you understand?&rdquo; or &ldquo;Do you have any questions?&rdquo;",
"     </li>",
"     <li>",
"      Limit teaching points to no more than three or four per session",
"     </li>",
"     <li>",
"      Repeat, reinforce and review teaching points at regular intervals",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6600030\">",
"    <span class=\"h2\">",
"     Skill development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although knowledge is an important component of self care, it is insufficient on its own. Many patients know facts about heart failure self management (ie, &ldquo;I should avoid salt&rdquo;) without having any corresponding skills to carry out that knowledge (ie, ability to read nutrition labels, identify high-salt foods in restaurants, etc). A list of the numerous skills patients must master to effectively manage their own care is presented above. (See",
"    <a class=\"local\" href=\"#H6599930\">",
"     'What constitutes appropriate self care?'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A few educational techniques may help to improve skill acquisition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Experiential learning: ie, have a patient read a prescription label and take out the correct amount of medication, calculate the amount of salt in a food product, or sort foods into high- and low-sodium categories.",
"     </li>",
"     <li>",
"      Role playing: ie, have a patient practice a conversation describing worsening symptoms to a health care provider",
"     </li>",
"     <li>",
"      Group sessions: group visits allow patients to learn from the experience of other, similarly-situated patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6600037\">",
"    <span class=\"h2\">",
"     Behavior change/patient engagement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most importantly, knowledge and skills are ineffective without patient engagement. Beliefs about treatment efficacy, for example, are an important predictor of adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/2,60\">",
"     2,60",
"    </a>",
"    ]. Patients who do not believe a treatment will be effective are unlikely to pursue the treatment no matter what their knowledge and skills. Similarly, recommendations and practices &ldquo;imposed&rdquo; by the physician or educator without patient involvement are less likely to be successful than ideas generated by patients themselves in collaboration with their care providers. Clinicians and educators can increase patient involvement in and engagement with their care in the following ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using motivational interviewing techniques (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=see_link&amp;anchor=H432862274#H432862274\">",
"       \"Overview of psychotherapies\", section on 'Motivational interviewing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Questioning patients explicitly about their beliefs in disease etiology and efficacy of treatment",
"     </li>",
"     <li>",
"      Engaging patients in developing a plan, and in filling out a notebook or monitoring materials",
"     </li>",
"     <li>",
"      Using brainstorming with patients to help them incorporate self-management into their lives: build on patients&rsquo; own experience and routines",
"     </li>",
"     <li>",
"      Helping patients identify one or two concrete actions they can do for each aspect of self care",
"     </li>",
"     <li>",
"      Having patients describe their self-management practices and offering feedback to improve them, rather than suggesting or imposing self-management practices",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6600128\">",
"    <span class=\"h1\">",
"     HEART FAILURE ACTION PLAN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major components of heart failure self care can be summarized in terms of a heart failure action plan. A heart failure action plan is divided into green, yellow, orange, and red zones corresponding to a stable state, worsening status, acute exacerbation, and cardiac emergency. The action plan includes a customized response plan for each state that is developed by the clinician in tandem with the patient (",
"    <a class=\"graphic graphic_figure graphicRef72459 \" href=\"UTD.htm?19/63/20474\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef75501 \" href=\"UTD.htm?31/48/32522\">",
"     figure 4",
"    </a>",
"    ). For most patients, symptoms in the yellow zone would require additional diuretic intake and renewed vigilance to diet and medication compliance. Symptoms in the orange zone should prompt an immediate call to the physician and rapid evaluation. Symptoms in the red zone should prompt a call for an ambulance. All patients should receive a heart failure action plan customized to their condition and abilities for self care.",
"   </p>",
"   <p>",
"    The 2010 HFSA guidelines recommend that patients have a HF action plan as a component of education and counseling focusing on self care [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25465/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=see_link\">",
"       \"Patient information: Heart failure (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/41/36499?source=see_link\">",
"       \"Patient information: Medicines for heart failure (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"       \"Patient information: Heart failure (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6600135\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinicians can promote effective self care by patients with heart failure by ensuring that patients have the knowledge, skills and engagement to appropriately carry out self care activities. (See",
"      <a class=\"local\" href=\"#H6599930\">",
"       'What constitutes appropriate self care?'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Knowledge should be taught using techniques such as teach-back and repetition",
"     </li>",
"     <li>",
"      Skills should be taught using techniques such as experiential learning.",
"     </li>",
"     <li>",
"      Beliefs and engagement should be encouraged using techniques such as motivational interviewing and patient-directed behavioral strategies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should be specifically instructed in the following self-care activities (See",
"      <a class=\"local\" href=\"#H6599930\">",
"       'What constitutes appropriate self care?'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Medication maintenance (for all patients)",
"     </li>",
"     <li>",
"      Medication management (for patients who are able to demonstrate sufficient knowledge and skills)",
"     </li>",
"     <li>",
"      Daily monitoring for",
"      <span class=\"nowrap\">",
"       signs/symptoms",
"      </span>",
"      (for all patients)",
"     </li>",
"     <li>",
"      Adherence to a low-sodium diet (for all patients)",
"     </li>",
"     <li>",
"      Smoking cessation and limited alcohol consumption",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients should receive a heart failure action plan detailing how they should respond to changes in clinical condition. (See",
"      <a class=\"local\" href=\"#H6600128\">",
"       'Heart failure action plan'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/1\">",
"      Jovicic A, Holroyd-Leduc JM, Straus SE. Effects of self-management intervention on health outcomes of patients with heart failure: a systematic review of randomized controlled trials. BMC Cardiovasc Disord 2006; 6:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/2\">",
"      van der Wal MH, Jaarsma T, Moser DK, et al. Compliance in heart failure patients: the importance of knowledge and beliefs. Eur Heart J 2006; 27:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/3\">",
"      Moser DK, Doering LV, Chung ML. Vulnerabilities of patients recovering from an exacerbation of chronic heart failure. Am Heart J 2005; 150:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/4\">",
"      WRITING GROUP MEMBERS, Lloyd-Jones D, Adams RJ, et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation 2010; 121:e46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/5\">",
"      Liu L. Changes in cardiovascular hospitalization and comorbidity of heart failure in the United States: findings from the National Hospital Discharge Surveys 1980-2006. Int J Cardiol 2011; 149:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/6\">",
"      Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med 2009; 360:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/7\">",
"      Chin MH, Goldman L. Factors contributing to the hospitalization of patients with congestive heart failure. Am J Public Health 1997; 87:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/8\">",
"      Riegel B, Lee CS, Dickson VV, Carlson B. An update on the self-care of heart failure index. J Cardiovasc Nurs 2009; 24:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/9\">",
"      Jaarsma T, Arestedt KF, M&aring;rtensson J, et al. The European Heart Failure Self-care Behaviour scale revised into a nine-item scale (EHFScB-9): a reliable and valid international instrument. Eur J Heart Fail 2009; 11:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/10\">",
"      Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/11\">",
"      Fowler MB, Vera-Llonch M, Oster G, et al. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group. J Am Coll Cardiol 2001; 37:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/12\">",
"      Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106:2194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/13\">",
"      Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000; 283:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/14\">",
"      Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100:2312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/15\">",
"      Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/16\">",
"      Carson P, Tognoni G, Cohn JN. Effect of Valsartan on hospitalization: results from Val-HeFT. J Card Fail 2003; 9:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/17\">",
"      Ostergren JB. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme. J Hypertens Suppl 2006; 24:S3.",
"     </a>",
"    </li>",
"    <li>",
"     Project RED: ReEngineered Discharge. 2009; file://www.bu.edu/fammed/projectred/. Accessed Jun 30, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/19\">",
"      Kripalani S, Robertson R, Love-Ghaffari MH, et al. Development of an illustrated medication schedule as a low-literacy patient education tool. Patient Educ Couns 2007; 66:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/20\">",
"      Cordasco KM, Asch SM, Bell DS, et al. A low-literacy medication education tool for safety-net hospital patients. Am J Prev Med 2009; 37:S209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/21\">",
"      DeWalt DA, Malone RM, Bryant ME, et al. A heart failure self-management program for patients of all literacy levels: a randomized, controlled trial [ISRCTN11535170]. BMC Health Serv Res 2006; 6:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/22\">",
"      Chaudhry SI, Wang Y, Concato J, et al. Patterns of weight change preceding hospitalization for heart failure. Circulation 2007; 116:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/23\">",
"      Brodovicz KG, McNaughton K, Uemura N, et al. Reliability and feasibility of methods to quantitatively assess peripheral edema. Clin Med Res 2009; 7:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/24\">",
"      Vinson JM, Rich MW, Sperry JC, et al. Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc 1990; 38:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/25\">",
"      Bennett SJ, Huster GA, Baker SL, et al. Characterization of the precipitants of hospitalization for heart failure decompensation. Am J Crit Care 1998; 7:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/26\">",
"      Tsuyuki RT, McKelvie RS, Arnold JM, et al. Acute precipitants of congestive heart failure exacerbations. Arch Intern Med 2001; 161:2337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/27\">",
"      Paterna S, Gaspare P, Fasullo S, et al. Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend? Clin Sci (Lond) 2008; 114:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/28\">",
"      Heart Failure Society of America. Nonpharmacologic management and health care maintenance in patients with chronic heart failure. J Card Fail 2010; 16:e61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/29\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     Cecil G. Sheps Center for Health Services Research. Caring for Your Heart: Living Well with Heart Failure. 2007; file://www.nchealthliteracy.org/hfselfmanage.html. Accessed June 30, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/31\">",
"      Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006; 27:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/32\">",
"      Wu JR, Moser DK, Lennie TA, Burkhart PV. Medication adherence in patients who have heart failure: a review of the literature. Nurs Clin North Am 2008; 43:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/33\">",
"      Butler J, Arbogast PG, Daugherty J, et al. Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. J Am Coll Cardiol 2004; 43:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/34\">",
"      Jackson JE, Doescher MP, Saver BG, Fishman P. Prescription drug coverage, health, and medication acquisition among seniors with one or more chronic conditions. Med Care 2004; 42:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/35\">",
"      Roe CM, Motheral BR, Teitelbaum F, Rich MW. Compliance with and dosing of angiotensin-converting-enzyme inhibitors before and after hospitalization. Am J Health Syst Pharm 2000; 57:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/36\">",
"      Lamb DA, Eurich DT, McAlister FA, et al. Changes in adherence to evidence-based medications in the first year after initial hospitalization for heart failure: observational cohort study from 1994 to 2003. Circ Cardiovasc Qual Outcomes 2009; 2:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/37\">",
"      Wu JR, Moser DK, De Jong MJ, et al. Defining an evidence-based cutpoint for medication adherence in heart failure. Am Heart J 2009; 157:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/38\">",
"      Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/39\">",
"      Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/40\">",
"      Stephenson BJ, Rowe BH, Haynes RB, et al. The rational clinical examination. Is this patient taking the treatment as prescribed? JAMA 1993; 269:2779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/41\">",
"      Evangelista LS, Shinnick MA. What do we know about adherence and self-care? J Cardiovasc Nurs 2008; 23:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/42\">",
"      O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009; 301:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/43\">",
"      Finkelstein MM. Medical conditions, medications, and urinary incontinence. Analysis of a population-based survey. Can Fam Physician 2002; 48:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/44\">",
"      Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/45\">",
"      Paasche-Orlow MK, Parker RM, Gazmararian JA, et al. The prevalence of limited health literacy. J Gen Intern Med 2005; 20:175.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. IOM report 2004. www.iom.edu (Accessed on January 11, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/47\">",
"      Davis TC, Wolf MS, Bass PF 3rd, et al. Literacy and misunderstanding prescription drug labels. Ann Intern Med 2006; 145:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/48\">",
"      Peterson PN, Shetterly SM, Clarke CL, et al. Health literacy and outcomes among patients with heart failure. JAMA 2011; 305:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/49\">",
"      Evangelista LS, Rasmusson KD, Laramee AS, et al. Health literacy and the patient with heart failure--implications for patient care and research: a consensus statement of the Heart Failure Society of America. J Card Fail 2010; 16:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/50\">",
"      Davis TC, Long SW, Jackson RH, et al. Rapid estimate of adult literacy in medicine: a shortened screening instrument. Fam Med 1993; 25:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/51\">",
"      Haworth JE, Moniz-Cook E, Clark AL, et al. Prevalence and predictors of anxiety and depression in a sample of chronic heart failure patients with left ventricular systolic dysfunction. Eur J Heart Fail 2005; 7:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/52\">",
"      Rutledge T, Reis VA, Linke SE, et al. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006; 48:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/53\">",
"      Riegel B, Moser DK, Anker SD, et al. State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. Circulation 2009; 120:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/54\">",
"      Morgan AL, Masoudi FA, Havranek EP, et al. Difficulty taking medications, depression, and health status in heart failure patients. J Card Fail 2006; 12:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/55\">",
"      Lesman-Leegte I, van Veldhuisen DJ, Hillege HL, et al. Depressive symptoms and outcomes in patients with heart failure: data from the COACH study. Eur J Heart Fail 2009; 11:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/56\">",
"      L&ouml;we B, Kroenke K, Gr&auml;fe K. Detecting and monitoring depression with a two-item questionnaire (PHQ-2). J Psychosom Res 2005; 58:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/57\">",
"      Pham HH, O'Malley AS, Bach PB, et al. Primary care physicians' links to other physicians through Medicare patients: the scope of care coordination. Ann Intern Med 2009; 150:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/58\">",
"      Heo S, Lennie TA, Moser DK, Okoli C. Heart failure patients' perceptions on nutrition and dietary adherence. Eur J Cardiovasc Nurs 2009; 8:323.",
"     </a>",
"    </li>",
"    <li>",
"     Doak CC, Doak LG, Root JH. Teaching patients with low literacy skills, 2nd ed, J. B. LIppincott, Philadelphia 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25465/abstract/60\">",
"      Ekman I, Andersson G, Boman K, et al. Adherence and perception of medication in patients with chronic heart failure during a five-year randomised trial. Patient Educ Couns 2006; 61:348.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13607 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-71969A6E96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_55_25465=[""].join("\n");
var outline_f24_55_25465=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6600135\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6599888\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6599895\">",
"      MAGNITUDE OF THE PROBLEM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6599902\">",
"      BENEFIT OF SELF-MANAGEMENT INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6599930\">",
"      WHAT CONSTITUTES APPROPRIATE SELF CARE?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6599937\">",
"      Medication management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6599953\">",
"      - Patient medication instructions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6599961\">",
"      - Instructions for patients able to perform medication management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6599971\">",
"      Daily monitoring of signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6599979\">",
"      - Daily weights",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6599987\">",
"      - Daily check for edema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6599995\">",
"      - Daily check of symptom severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6600002\">",
"      Adherence to sodium restricted diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9750301\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6600009\">",
"      Smoking cessation and alcohol use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20636816\">",
"      OBSERVED RATES OF ADHERENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20636823\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20636830\">",
"      Daily weights",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20636837\">",
"      Symptom monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20636844\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20636851\">",
"      Sodium-restricted diet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20637567\">",
"      BARRIERS TO SELF CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20637574\">",
"      Socioeconomic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20637581\">",
"      Therapy-related factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20637588\">",
"      Patient factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20637595\">",
"      - Low health literacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20637602\">",
"      - Multimorbidity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20637609\">",
"      - Depression and anxiety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20637616\">",
"      - Healthcare team/system factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H90371077\">",
"      PROMOTING EFFECTIVE SELF-CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6600023\">",
"      Knowledge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6600030\">",
"      Skill development",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6600037\">",
"      Behavior change/patient engagement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6600128\">",
"      HEART FAILURE ACTION PLAN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6600135\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/13607\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/13607|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/52/1864\" title=\"figure 1\">",
"      Chart for medication management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/61/5079\" title=\"figure 2\">",
"      Definition standard drink",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/63/20474\" title=\"figure 3\">",
"      Heart failure action plan - page 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/48/32522\" title=\"figure 4\">",
"      Heart failure action plan - page 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/13607|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35672?source=related_link\">",
"      Alcoholic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=related_link\">",
"      Cardiac rehabilitation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=related_link\">",
"      Cardiovascular benefits and risks of moderate alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/42/19111?source=related_link\">",
"      Compliance with lipid altering medications and recommended lifestyle changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/3/42039?source=related_link\">",
"      Drugs that should be avoided or used with caution in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17609?source=related_link\">",
"      Literacy and patient care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23828?source=related_link\">",
"      Patient adherence and the treatment of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/41/36499?source=related_link\">",
"      Patient information: Medicines for heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24120?source=related_link\">",
"      Salt intake, salt restriction, and essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37929?source=related_link\">",
"      Strategies to reduce hospitalizations in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33446?source=related_link\">",
"      Treatment of acute decompensated heart failure in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_55_25466="Devices for difficult emergency airway management in adults";
var content_f24_55_25466=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Devices for difficult emergency airway management in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/55/25466/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/55/25466/contributors\">",
"     Erik G Laurin, MD, FAAEM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/55/25466/contributors\">",
"     Aaron E Bair, MD, MSc, FAAEM, FACEP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/55/25466/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/55/25466/contributors\">",
"     Ron M Walls, MD, FRCPC, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/55/25466/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/55/25466/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/55/25466/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergency clinicians commonly encounter difficult airways. Estimates run as high as 20 percent for difficult airways [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/1\">",
"     1",
"    </a>",
"    ] and approximately 1 percent for failed airways [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/2\">",
"     2",
"    </a>",
"    ]. Difficulty in airway management is variably defined, and includes the need for excess lifting force, poor view of the vocal cords, multiple or prolonged attempts, multiple operators, and the use of multiple intubating devices.",
"   </p>",
"   <p>",
"    A wide range of devices have been developed to aid in the management of the difficult airway. They incorporate a variety of fiberoptic, video, optical, and mechanical technologies to enable the operator to obtain a better view of the larynx and facilitate passage of an endotracheal tube (ETT) into the trachea. These devices are useful for management of the difficult or failed airway and for routine intubation.",
"   </p>",
"   <p>",
"    This topic review will discuss the types of devices designed to facilitate management of difficult and failed airways. The overall approach to the management of such airways is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=see_link\">",
"     \"The difficult airway in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18228?source=see_link\">",
"     \"The failed airway in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=see_link\">",
"     \"The difficult pediatric airway\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STYLETS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We define a stylet as a device loaded within the lumen of an endotracheal tube (ETT) in order to assist tracheal placement. A standard malleable metal stylet is inserted into an ETT to lend greater stiffness and thereby improve control. In contrast, specialized stylets facilitate intubation in situations of poor glottic exposure and if adapted with advanced optics, can provide a better view of the glottis than is obtained with direct laryngoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Endotracheal tube introducers (gum elastic bougie)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endotracheal tube introducer (ETI) is an effective and inexpensive adjunct to difficult airway management that is easy to use. We recommend that an ETI be readily available in every emergency department.",
"   </p>",
"   <p>",
"    Several terms are used to describe the classic ETI. Although the term \"gum elastic bougie\" is common, we find it confusing since the ETI is neither gum nor elastic and is not used as a bougie (ie, dilator).",
"   </p>",
"   <p>",
"    The ETI consists of a 60 cm stylet with the distal tip bent at a 30 degree angle (",
"    <a class=\"graphic graphic_figure graphicRef55895 \" href=\"UTD.htm?20/30/20974\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef63503 \" href=\"UTD.htm?20/24/20864\">",
"     figure 2",
"    </a>",
"    ). The bend allows the intubator to direct the tip anteriorly under the epiglottis and through the vocal cords, which may not be visible. When advancing the ETI, the intubator must be careful to maintain the bent tip in the midline and not allow it to rotate to either side; otherwise, the anteriorly located tracheal rings will not be appreciated.",
"   </p>",
"   <p>",
"    Two tactile sensations confirm correct placement in the trachea [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. One sign is the feeling of vibrations or \"clicks\" as the tip of the ETI is advanced over the tracheal rings. Another sign is resistance to further insertion. As the introducer advances to between 24 and 40 cm from the teeth, the distal tip becomes lodged in smaller airways and cannot advance. If the ETI is in the esophagus, the tracheal rings cannot be felt and the introducer advances easily into the stomach. In a study using 20 human cadavers, clinicians without prior experience using an ETI were able, using the techniques described here, to determine esophageal placement in 95 percent of cases (95% CI 88-98) and tracheal placement in 93 percent (95% CI 86-97) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the ETI is placed in the trachea, an ETT is threaded over it using a Seldinger-like technique. This generally requires an assistant to place the ETT on the proximal end of the introducer. The intubator then advances the ETT over the introducer into the trachea and the introducer is withdrawn.",
"   </p>",
"   <p>",
"    The following tips may facilitate placement of the ETT over the introducer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Throughout the procedure, the operator should maintain proper position of the laryngoscope with the left hand. The tendency is to remove the laryngoscope after the introducer is in the trachea, but doing so allows the tongue to fall posteriorly and potentially hinder tube passage.",
"     </li>",
"     <li>",
"      Passage of the ETT is easier if it is close in size to the introducer. The greater the disparity, the more likely the ETT will catch on the arytenoids during insertion. This may require using a smaller ETT than would otherwise be used, but this is a small price to pay for success in a difficult situation.",
"     </li>",
"     <li>",
"      If the ETT impinges on the arytenoids, slight withdrawal of the ETT (to disengage the tip from the arytenoids), followed by careful counterclockwise rotation and relaxation of cricoid pressure (if used) may facilitate passage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dimensions and use are comparable among the three types of ETI available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eschmann Introducer&reg; &ndash; Woven Dacron rod with resin coating, can be sterilized and reused. This is commonly referred to as a \"gum elastic bougie.\"",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       SunMed&reg;/Flex",
"      </span>",
"      Guide&reg; &ndash; Solid polyethylene, single use (",
"      <a class=\"graphic graphic_figure graphicRef63503 \" href=\"UTD.htm?20/24/20864\">",
"       figure 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Frova&reg; &ndash; Hollow, single use plastic introducer with fenestrated tip to allow oxygenation; includes 15 mm adapter for standard bag-valve assembly (",
"      <a class=\"graphic graphic_figure graphicRef55895 \" href=\"UTD.htm?20/30/20974\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the Eschmann introducer is more expensive, it can be used multiple times, so the average cost per intubation is comparably inexpensive to that of a single use introducer. Nevertheless, some clinicians prefer single use introducers because multiple use introducers are sometimes inadvertently thrown away. The plastic of the SunMed&reg; stylet has \"memory,\" so J-shaped anterior curvatures can be maintained for use with video devices. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Scopes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Multiple randomized and observational trials demonstrate that ETIs aid intubation, especially with grade 3 glottic views (",
"    <a class=\"graphic graphic_figure graphicRef55034 \" href=\"UTD.htm?34/2/34863\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. Little training is needed before introducers can be used successfully [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. This is likely because of the similarity to standard intubating technique and familiarity with the Seldinger method. In an observational study of prehospital airway management, physicians used an ETI to intubate 78 percent of difficult airways in which standard techniques had failed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Novel uses of ETIs include distinguishing tracheal from esophageal ETT placement [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/3,11\">",
"     3,11",
"    </a>",
"    ]. Although this approach has been advocated in cardiac arrest patients, where end-tidal CO2 may not be measurable, there is insufficient evidence to recommend that introducers be used for this purpose. Complications from airway introducers are rare and involve mechanical trauma to airway structures [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other fiberoptic or video devices may provide greater assistance managing difficult airways [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], but most such devices, including optical stylets, flexible endoscopes, and video laryngoscopes, are comparatively expensive and may require more training.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Lighted stylets",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lighted stylet is a useful tool for difficult airway management, particularly in patients with an anterior airway. It is not useful in patients with distorted upper airway anatomy. The intubator must develop and maintain facility with the device.",
"   </p>",
"   <p>",
"    A lighted stylet, such as the Trachlight&reg;, relies on a bright light at the distal tip of the device to transilluminate the glottis through the soft tissues of the neck, thereby providing indirect visual confirmation of tracheal placement. Intubation using a lighted stylet does not depend on direct visualization of internal structures. Proper application relies largely upon recognizing midline (ie, tracheal) versus lateral (soft tissue) or esophageal placement of the device.",
"   </p>",
"   <p>",
"    Observational studies support the use of lighted stylets in routine and difficult airway management; however, acquisition of skill with the technique requires 10 to 20 intubations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. Inexperienced users have longer times to intubation and lower success rates compared with direct laryngoscopy (DL) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/15-17,19\">",
"     15-17,19",
"    </a>",
"    ]. With more experienced users, first pass intubation success rates using lighted stylets are as high as 93 percent and discrepancies with DL in the time needed for intubation diminish [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/18,20-22\">",
"     18,20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advantages of lighted stylet intubation include utility in managing difficult anterior airways [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/18,21,23\">",
"     18,21,23",
"    </a>",
"    ], less risk of pharyngeal trauma compared with DL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/18,24\">",
"     18,24",
"    </a>",
"    ], the ability to intubate when the glottis cannot be adequately visualized by DL, and less cervical spine motion compared with DL or the Glidescope&reg; [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Hemodynamic responses to lighted stylet intubation are similar or less than with DL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/22,23,28,29\">",
"     22,23,28,29",
"    </a>",
"    ]. The lighted stylet can be used for nasotracheal intubations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/1,30\">",
"     1,30",
"    </a>",
"    ] and to aid placement of ETTs using an intubating laryngeal mask airway (ILMA) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lighted stylet intubation is not recommended in patients with abnormal or distorted upper airway anatomy, such as traumatic injuries, tumors, infections, or foreign bodies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The light of the Trachlight&reg; is bright enough for the transilluminated glow to be seen in ambient light, but room lights may need to be dimmed for the glow to show through thick subcutaneous tissue or deeply pigmented skin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Optical stylets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optical stylets (OS) incorporate a fiberoptic or video viewing element into the distal end of a metal stylet. The stylet can be rigid, semirigid, or directable. The viewing element effectively moves the intubator's view from outside the mouth to the tip of the OS and closer to the glottis. The OS can be useful in patients with a difficult airway. In the absence of obstructing debris, the OS can provide an improved view of the vocal cords and ensure passage of the endotracheal tube (ETT) into the trachea under direct visualization.",
"   </p>",
"   <p>",
"    The OS, although more expensive than a lighted stylet, is typically less expensive than other video and fiberoptic laryngoscopes. Like any nontraditional method of laryngoscopy, the OS requires skill acquisition and maintenance to be used effectively.",
"   </p>",
"   <p>",
"    All OS devices have an eyepiece for viewing the glottis, and some can be connected to an external monitor for ease of use, teaching, or supervision. Several of these devices also have a side port to insufflate oxygen in order to prevent secretions from obscuring the fiberoptic tip of the stylet. Common examples of the OS include the Clarus Video System, Shikani Optical Stylet, Bonfils Retromolar Intubation Fiberscope (",
"    <a class=\"graphic graphic_picture graphicRef63259 \" href=\"UTD.htm?10/35/10802\">",
"     picture 1",
"    </a>",
"    ), Levitan FPS Scope, and Airway RIFL.",
"   </p>",
"   <p>",
"    When performing endotracheal intubation using the OS, the ETT is mounted on the stylet. The OS is then inserted, often without the aid of a direct laryngoscope, and the relevant anatomic structures visualized through the proximal eyepiece as the stylet is advanced and then navigated through the vocal cords and into the trachea. Once the tracheal rings are visualized, the tube is advanced off the stylet, and the stylet withdrawn.",
"   </p>",
"   <p>",
"    Alternatively, the OS can be used to supplement standard direct laryngoscopy (DL). The ETT is loaded onto the OS and oxygen is attached to the side port, if present. DL is performed, and the intubator can choose to look through the eyepiece or directly at the glottis to watch the ETT pass the cords. Regardless of placement technique, the intubator can look through the OS to determine proper insertion depth by visualizing the carina three to four tracheal rings away from the tip of the ETT.",
"   </p>",
"   <p>",
"    There are few studies comparing the OS to other devices, and none in emergency department (ED) patients. Clinical trials using simulated difficult airways report mixed results. A randomized trial of 60 patients comparing one type of OS with a videolaryngoscope reported high first pass intubation success rates with either technique [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/34\">",
"     34",
"    </a>",
"    ]. However, a similar trial involving 94 patients that compared another type of OS with direct laryngoscopy using a Macintosh laryngoscope reported that the simulated difficult airway (created with manual cervical spine immobilization) could not be intubated using the OS in 20 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The OS appears most useful in cases with limited vocal cord visibility. However, results are difficult to extrapolate to some ED patients, in whom secretions, blood, and debris may reduce utility. Intubation using an OS may reduce cervical spine motion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/27\">",
"     27",
"    </a>",
"    ] and alterations in hemodynamic measures [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/36\">",
"     36",
"    </a>",
"    ] compared with standard DL, but data are scant. An OS is typically thousands of dollars less than other fiberoptic and video devices [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Flexible endoscope",
"    </span>",
"    &nbsp;&mdash;&nbsp;The flexible endoscope (FE) is essentially a 60 cm long flexible and directable stylet that can be used for airway management in patients for whom difficult intubation is predicted and neuromuscular paralysis is best avoided. Because of the time required and the patient preparation necessary, intubation using a FE is generally not performed in patients who require immediate establishment of an airway. If time allows for adequate patient preparation, the FE is an invaluable intubating device.",
"   </p>",
"   <p>",
"    Among the devices used for difficult airway management, the FE has a unique set of characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The FE can be used for either orotracheal or nasotracheal intubation. Nasotracheal use allows access to the vocal cords when mouth opening is limited.",
"     </li>",
"     <li>",
"      The FE can be used with adjunctive devices, such as specially designed oral airways, that improve intubation success.",
"     </li>",
"     <li>",
"      More time is required to perform intubation using the FE. Patients must be cooperative (usually achieved by using sedation and topical anesthesia), breathing spontaneously, and adequately oxygenated.",
"     </li>",
"     <li>",
"      Clinicians must practice longer and more often to acquire and maintain facility with the FE compared with other airway devices.",
"     </li>",
"     <li>",
"      The cost of purchasing and maintaining a FE is higher than for most other devices.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these limitations to FE use for emergent airway management, a survey in 1999 found that 64 percent of academic EDs had an FE [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Indications for FE use include a difficult airway due to limited mouth opening, oral obstructions from infection, hematoma, or angioedema, and upper airway anatomic abnormalities from masses, operations, trauma, or head and neck contractures.",
"   </p>",
"   <p>",
"    Relative contraindications include copious secretions or blood and a rapidly worsening supraglottic obstruction, such as a foreign body, with imminent airway compromise.",
"   </p>",
"   <p>",
"    Nasotracheal intubation with the FE offers some advantages, but some clinicians find it more difficult to perform than its oral counterpart because of the greater distances and angles to be negotiated. The nasal route is often better tolerated by the patient and eliminates the risk of the patient biting the endoscope and damaging the fiberoptic bundles. Passage of the scope and ETT through the nasopharynx can cause bleeding, which obscures visualization. Therefore, application of a vasoconstrictor (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/54/33632?source=see_link\">",
"     oxymetazoline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    , cocaine) prior to the procedure is important to minimize this risk.",
"   </p>",
"   <p>",
"    We recommend that the intubator insert the well-lubricated endotracheal tube first, passing it through the naris and into the nasopharynx, and then insert the FE through the lumen of the tube. This eliminates the possibility that the operator will be unable to successfully pass the tube into and through the naris after the vocal cords are traversed by the FE. Placing the ETT too deep, however, hinders scope manipulation by creating too acute an angle for the scope to traverse in order to reach the glottis.",
"   </p>",
"   <p>",
"    If orotracheal intubation is desired, bite blocks are necessary to prevent the patient from biting the FE. Specialized airways (eg, Berman Breakaway Airway) designed for use with the FE and shaped to direct the tip of the scope towards the glottis are available. FEs can also be placed through a laryngeal mask airway (LMA) or similar device to facilitate endotracheal intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38135?source=see_link\">",
"     \"Flexible bronchoscopy: Indications and contraindications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While a complete tutorial of flexible endoscopes is beyond the scope of this review, there are a few technical points worth highlighting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recognize that the procedure often requires 5 to 20 minutes. If the patient cannot tolerate such a delay, the technique should not be used.",
"     </li>",
"     <li>",
"      Stay in the anatomic midline at all times during the procedure. Straying laterally often results in poor visualization and inability to pass the FE through the vocal cords.",
"     </li>",
"     <li>",
"      The operator should keep the FE taut between both hands. If slack is present, rotation of the body of the FE will not translate into rotation of the tip.",
"     </li>",
"     <li>",
"      In many of the smaller scopes used for intubation, suction through the working channel is ineffective at clearing the field of view.",
"     </li>",
"     <li>",
"      Intermittent insufflation of oxygen through the working channel can be useful to clear debris from the scope tip. However, prolonged insufflation can result in barotrauma [",
"      <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If there is difficulty passing the ETT off the FE and into the airway, the ETT tip is likely caught at the level of the arytenoids. Counter-clockwise rotation of the entire tube-scope apparatus will likely overcome the obstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies have shown that emergency clinicians performing FE intubations have a success rate between 56 and 99 percent, depending upon the operator's level of experience [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/44-48\">",
"     44-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Flexible endoscopes typically cost thousands of dollars (US), and can be fragile and difficult to maintain in an ED environment. A single use, disposable alternative is available in the Ambu&copy; aScope. In this device, the disposable video scope and handle connect to a reusable video screen. No studies have been published that assess the aScope in emergency airway management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EXTRAGLOTTIC DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extraglottic devices are those that establish an airway for oxygenation and ventilation without traversing the glottis. They are critical tools for the management of difficult and failed airways. The most commonly used extraglottic devices are the Laryngeal Mask Airway&trade; (LMA&trade;), Combitube&trade;, and laryngeal tubes. We recommend that clinicians responsible for airway management be familiar with at least one such device, particularly for use in patients that cannot be adequately ventilated using a bag-mask.",
"   </p>",
"   <p>",
"    In emergency airway management, an extraglottic device can be used to provide ventilation until a definitive airway is established. In some circumstances, it can be used to convert a \"can't intubate, can't ventilate\" situation into a \"can't intubate, CAN ventilate\" one, provided placing the extraglottic device does not delay initiation of a surgical airway. A surgical airway is the recommended approach in the \"can't intubate, can't ventilate\" scenario. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18228?source=see_link\">",
"     \"The failed airway in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Few studies comparing extraglottic airway devices have been performed and data regarding superiority of one over another are lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. The Combitube&trade;, because of its two cuffs, may take longer to place before the first ventilation is given [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/49\">",
"     49",
"    </a>",
"    ]. The intubating LMA&trade;, Intubating Laryngeal Airway&trade; (ILA&trade;), and the King LT&copy; (laryngeal tube) (",
"    <a class=\"graphic graphic_figure graphicRef67135 \" href=\"UTD.htm?39/52/40783\">",
"     figure 4",
"    </a>",
"    ) are the only extraglottic airways designed to enable placement of a definitive airway, and may be more appropriate for failed airway management in the emergency department. Each device type is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laryngeal mask airways",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Laryngeal Mask Airway&trade; (LMA&trade;) (",
"    <a class=\"graphic graphic_picture graphicRef63766 \" href=\"UTD.htm?38/20/39247\">",
"     picture 2",
"    </a>",
"    ) and Intubating Laryngeal Airway&trade; (ILA&trade;) (",
"    <a class=\"graphic graphic_picture graphicRef63844 \" href=\"UTD.htm?21/43/22207\">",
"     picture 3",
"    </a>",
"    ) are two devices designed to create a mask seal over the laryngeal inlet to ventilate and oxygenate patients for short to intermediate periods during elective anesthesia or emergency airway management. The mask portions of each of these devices are similar in shape, but the ILA&trade; mask is slightly stiffer to prevent folding of the leading edge during insertion.",
"   </p>",
"   <p>",
"    Many clinicians have familiarity with laryngeal mask airways, making them useful tools for the management of difficult airways. Several models are commercially available. We suggest the use of models that allow for placement of a cuffed endotracheal tube (ETT) in the trachea through the device (eg, Intubating LMA&trade; or ILA&trade;). Multiple observational studies support the use of the ILMA&trade; in difficult airway management [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/51-64\">",
"     51-64",
"    </a>",
"    ]. Intubation success rates using intubating LMAs are about 95 percent, comparable to those for flexible endoscopic intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/65\">",
"     65",
"    </a>",
"    ]. Intubation can be attempted through a standard (ie, nonintubating) LMA, and the success rate, while lower, remains above 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The LMA&trade; is produced in several forms, including the LMA Classic&trade;, LMA Unique&trade;, LMA Flexible&trade;, LMA ProSeal&trade;, LMA Supreme&trade;, and LMA Fastrach&trade; (ie, intubating LMA&trade; or ILMA&trade;). There is also an LMA CTrach&trade; that is similar to the Fastrach&trade;, but with an integrated camera and screen to visualize the glottic opening for easier passage of an ETT.",
"   </p>",
"   <p>",
"    The i-gel&trade; is similar to an LMA but uses a noninflatable cuff and wider tubing for stability. The device is made from a flexible polymer that seals the glottic opening through its anatomic shape. The ventilation lumen is large enough to pass standard ETTs, and a bite block and gastric suction channel are integrated into the device.",
"   </p>",
"   <p>",
"    Randomized and large observational studies suggest the i-gel&trade; may be an effective tool for difficult airway management [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/67-69\">",
"     67-69",
"    </a>",
"    ], although blind intubation may be more difficult compared with the ILMA [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/70\">",
"     70",
"    </a>",
"    ]. The i-gel&trade; may be useful for air-medical transport as it does not use an air-filled cuff that is subject to pressure changes at varying altitudes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/71\">",
"     71",
"    </a>",
"    ]. Additionally, it is possible to place a flexible endoscope (FE) inside an ETT and steer the FE into the trachea under direct vision via the i-gel&trade;, and then railroad the ETT over the FE into the trachea to establish a definitive airway.",
"   </p>",
"   <p>",
"    The following discussion will focus on the LMA Fastrach&trade; (",
"    <a class=\"graphic graphic_picture graphicRef63844 \" href=\"UTD.htm?21/43/22207\">",
"     picture 3",
"    </a>",
"    ), since the mask seal is the same as the other varieties and it is the only type that has been well studied for blind ETT passage into the trachea.",
"   </p>",
"   <p>",
"    While a complete tutorial of ILMA&trade; insertion is beyond the scope of this review, several items are worth highlighting. The handle of the ILMA&trade; allows easier manipulation of the device and does not require the operator to place fingers inside the patient's mouth to guide placement. Once the ILMA&trade; is placed in the hypopharynx and the cuff is inflated, bag ventilation can be performed.",
"   </p>",
"   <p>",
"    Adequate ventilation implies good ILMA&trade; positioning. The proprietary nonkinking ETT can then be advanced through the lumen of the ILMA&trade;. After confirmation of proper ETT placement, the ILMA&trade; cuff is deflated, and the ILMA&trade; removed over the ETT, leaving the ETT in place as a definitive airway. The technique involves multiple steps and has potential pitfalls, so clinicians must have practiced it before using it in a failed airway.",
"   </p>",
"   <p>",
"    Use of the ILA&trade; differs. Once positioned for ventilation, the ILA&trade; allows passage of a standard ETT through its tubing into the trachea. This eliminates some of the complexity associated with the ILMA&trade;. The device has yet to be studied extensively in clinical situations. The ILA&trade; is a multiple-use device, although the manufacturer produces a single-use version called the Air-Q&trade;.",
"   </p>",
"   <p>",
"    Anesthesia studies report the ILMA&trade; is effective in managing difficult and failed airways [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/52-58,72\">",
"     52-58,72",
"    </a>",
"    ], but its performance in ED airway management has not been adequately studied [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/53,59-64,73\">",
"     53,59-64,73",
"    </a>",
"    ]. Contraindications to using the ILMA&trade; include abnormal supraglottic or glottic anatomy that may prevent mask seal and alignment or obstruct airflow.",
"   </p>",
"   <p>",
"    While such problems are not common, ventilation may be difficult and cuff leaks can occur when using an ILMA&trade;. This may be due to improper head and neck positioning, so attention must be paid to keeping the head and neck neutral and the ILMA&trade; midline [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. A retrospective observational study of the LMA Unique&trade; in 15,795 patients undergoing elective ambulatory surgery reported a failure rate of 1.1 percent, with cuff leaks being the most common problem [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/77\">",
"     77",
"    </a>",
"    ]. In this study, the most important risk factor for LMA failure was intraoperative surgical table rotation, which may be analogous to patient movement within and between beds in the ED. Such movements may displace the LMA and disrupt the glottic seal. Other important risk factors for LMA failure identified in the study included obesity and poor dentition. It is not known whether such problems occur less often with the ILMA&trade;, in which lifting the handle (so-called &ldquo;frying pan&rdquo; lift) improves the seal of the cuff on the glottis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A single-use, disposable version of the Fastrach&trade; exists and was equivalent to the reusable ILMA&trade; in clinical studies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/78\">",
"     78",
"    </a>",
"    ]. Success rates, time to intubation, and skill retention for LMA&trade; placement are variable when compared with other extraglottic devices (Combitube&trade;, laryngeal tube, Cobra-PLA&trade;), but appear similar in most studies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/51,79-83\">",
"     51,79-83",
"    </a>",
"    ]. One case series demonstrated a high success rate for the CTrach&trade; in the ventilation and intubation of morbidly obese patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/84\">",
"     84",
"    </a>",
"    ]. Data are insufficient to compare the ILMA&trade; with other extraglottic devices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Combitube&trade;",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Combitube&trade; is a dual-lumen, dual-cuff airway designed for esophageal placement. One cuff lies above the glottis and the other is distal to the glottis in the esophagus, thereby isolating the laryngeal inlet and allowing for directed ventilation into the trachea.",
"   </p>",
"   <p>",
"    The Combitube&trade; has been used extensively for general anesthesia and has been studied in out-of-hospital cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. Despite the documented success of the Combitube&trade; in difficult airway management, we prefer extraglottic devices that allow for the establishment of a cuffed endotracheal tube in the trachea (ie, definitive airway). It is not possible to establish a definitive airway through the Combitube&trade;.",
"   </p>",
"   <p>",
"    Indications for the Combitube&trade; include the need for ventilation and oxygenation in an unconscious, unresponsive, or paralyzed patient. Contraindications include pharyngeal or glottic pathology that may prevent cuff seal or cause injury from direct cuff pressure. Such cases include caustic ingestions and laryngeal foreign bodies.",
"   </p>",
"   <p>",
"    Insertion of the Combitube&trade; is a blind technique, but a laryngoscope may be used to assist placement by improving access to the oropharynx. Placement is straightforward and ventilation is generally effective in difficult and failed airways [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/85,87-95\">",
"     85,87-95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Combitube's&trade; effectiveness at protecting the airway from aspiration of gastric contents is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/96\">",
"     96",
"    </a>",
"    ]. Complications involving mucosal ischemia, pyriform sinus perforation, and esophageal rupture have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/93,97-106\">",
"     93,97-106",
"    </a>",
"    ], so care must be taken to minimize cuff inflation pressures and the total time the Combitube&trade; is in place before a definitive airway is established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Laryngeal and pharyngeal tubes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngeal tubes were developed subsequently to the LMA&trade; and Combitube&trade; so data supporting their use are more limited. Their ease of use makes many of these devices attractive in difficult airway situations, and some allow for the establishment of a definitive airway.",
"   </p>",
"   <p>",
"    The King LT&copy; and the Glottic Aperture Seal Airway&trade; (GO2 Airway&trade;) are examples of laryngeal tubes (",
"    <a class=\"graphic graphic_picture graphicRef79762 \" href=\"UTD.htm?32/35/33343\">",
"     picture 4",
"    </a>",
"    ). Pharyngeal tubes, such as the Cuffed Oropharyngeal Airway&trade; (COPA&trade;) and Pharyngeal Airway Xpress&trade; (PAX&trade;), have been used longer, but there are insufficient data to evaluate their clinical performance in emergency airway management.",
"   </p>",
"   <p>",
"    This section discusses the King LT&copy; primarily because there is greater clinical experience with it. Like the Combitube&trade;, the King LT&copy; has a pharyngeal cuff and an esophageal cuff, with a port between the cuffs at the level of the laryngeal inlet to allow gas exchange (and instrument passage) (",
"    <a class=\"graphic graphic_figure graphicRef67135 \" href=\"UTD.htm?39/52/40783\">",
"     figure 4",
"    </a>",
"    ). It is shorter than the Combitube&trade;, has one large lumen instead of two smaller ones, and uses only one inflation valve to fill both cuffs.",
"   </p>",
"   <p>",
"    Like the ILMA&trade; and Combitube&trade;, indications for use of these devices in emergency airway management include the need for ventilation and oxygenation in an unconscious, unresponsive, or paralyzed patient. Contraindications include pharyngeal or glottic pathology that may prevent cuff seal or the potential of damage from direct cuff pressure (eg, caustic ingestions, laryngeal foreign bodies).",
"   </p>",
"   <p>",
"    In an observational study of prehospital airway management, the King LT&copy; provided successful rescue airways in all 26 patients with no immediate complications and no surgical airways needed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/107\">",
"     107",
"    </a>",
"    ]. Studies performed on manikins or in the operating room during management of controlled airways show that time to ventilation and successful placement of the laryngeal tube is on par with the LMA&trade; and significantly faster than endotracheal intubation using direct laryngoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/79-83,108\">",
"     79-83,108",
"    </a>",
"    ]. One prospective observational study found the laryngeal tube maintained effective cuff seals even in the presence of supraglottic tumors in 22 of 23 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The King LT&copy; has other advantages. Like an LMA&trade;, the ventilating tube is large enough to pass a bronchoscope to visualize the glottis and troubleshoot difficult intubations. The device can accommodate an endotracheal tube introducer (ETI) but complications using this approach in manikins have been reported and we do not recommend it, pending further study [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SCOPES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Video laryngoscopes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rigorous randomized trials to assess the performance of video laryngoscopes in emergency airway management are lacking. Nevertheless, based upon our clinical experience and available data, we believe these devices are highly effective and can help emergency clinicians maximize first-pass intubation success in both routine and difficult airway scenarios [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/111\">",
"     111",
"    </a>",
"    ]. Multiple controlled and observational studies report that video laryngoscopes as a class provide superior views of the glottis compared with direct laryngoscopy (DL) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/112-118\">",
"     112-118",
"    </a>",
"    ] and cause minimal movement of the cervical spine during intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/27,119-121\">",
"     27,119-121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Video laryngoscopes are easy to use and build upon basic DL techniques, although some training and adjustments in technique are needed. Furthermore, unlike DL, video laryngoscopes provide the supervisor and trainee with an identical view of the glottis, allowing for improved teaching and troubleshooting.",
"   </p>",
"   <p>",
"    Video laryngoscopes use fiberoptics or a micro video camera encased in a laryngoscope to provide a wide-angle view of the glottis. The optics are set back from the tip of the laryngoscope blade, minimizing interference from secretions. Devices with micro video cameras are less expensive and more durable than flexible fiberoptics, which use glass fiber. Examples of video laryngoscopes include the GlideScope (",
"    <a class=\"graphic graphic_picture graphicRef59169 \" href=\"UTD.htm?12/18/12576\">",
"     picture 5",
"    </a>",
"    ), Pentax Airway Scope (",
"    <a class=\"graphic graphic_picture graphicRef85754 \" href=\"UTD.htm?32/62/33775\">",
"     picture 6",
"    </a>",
"    ), McGrath Video Laryngoscope (",
"    <a class=\"graphic graphic_figure graphicRef55142 \" href=\"UTD.htm?11/17/11551\">",
"     figure 5",
"    </a>",
"    ), and the Storz CMAC video laryngoscope (",
"    <a class=\"graphic graphic_picture graphicRef57154 \" href=\"UTD.htm?27/3/27700\">",
"     picture 7",
"    </a>",
"    ). Few studies have directly compared the performance of one video laryngoscope to another. One retrospective study of 463 intubations performed in the emergency department reported similar rates of first-pass and overall intubation success with the Glidescope and the CMAC [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of video laryngoscopes varies, depending upon the configuration of the blade. The blade most often is inserted midline and no tongue sweep is required. With the Glidescope, once fully inserted, with the blade tip at the base of the tongue, the device is tilted slightly, rather than lifted, so that the tip of the blade is oriented directly towards the epiglottis. Only a slight lift, if any at all, is applied since the curve of the blade corresponds to the shape of the airway. The ETT stylet requires a 90 degree bend just proximal to the cuff in order to follow the shape of the blade into the glottis. In a randomized trial of surgical patients intubated using the Glidescope, a 90 degree angle improved the ease of intubation, but neither forward nor reverse orientation of ETT camber affected performance [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the ETT is seen entering the vocal cords, the stylet needs to be partially withdrawn to allow the ETT to advance into the trachea. This step can sometimes be challenging, and the manufacturer provides a custom-made rigid stylet to facilitate this action. According to a retrospective study of 473 emergency department intubations, use of the custom-made rigid stylet is associated with higher rates of successful intubation, both at the first attempt and overall [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/124\">",
"     124",
"    </a>",
"    ]. However, this is in contrast to an operating room report in which the Glidescope proprietary stylet and a standard malleable stylet were found to be equally effective when used by experienced anesthesiologists [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/125\">",
"     125",
"    </a>",
"    ]. Further research is needed to address the question of stylet use.",
"   </p>",
"   <p>",
"    The Glidescope&reg; is currently available in three models. The original Glidescope&reg; has a reusable video laryngoscope and separate mounted video screen. The Glidescope&reg; Cobalt system provides a single use option. The Cobalt system relies upon a small video baton that fits into a disposable plastic laryngoscope blade. This eliminates the need for sterilization and minimizes the risk of equipment damage or loss. The Cobalt system works with both the mounted and portable systems. The Glidescope&reg; Ranger is a handheld version, with the video laryngoscope connected by a short wire to a durable battery-operated screen. The Glidescope&reg; laryngoscope sizes correspond roughly to a Macintosh number 3 and number 2, as well as a neonatal size.",
"   </p>",
"   <p>",
"    Emergency department (ED) experience with video laryngoscopes in difficult or failed airways is limited. Anesthesia literature suggests the GlideScope&reg; provides a better view of the glottis than DL, requires less time to intubation, and leads to higher rates of successful intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/113,117,126-131\">",
"     113,117,126-131",
"    </a>",
"    ]. A meta-analysis of six controlled studies of difficult intubation (involving 264 patients) reported that a superior glottic view (Cormack-Lehane grade 1) was achieved significantly more often using the Glidescope&reg; compared to a direct laryngoscope (RR 3.52; 95% CI 2.26-5.48) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When using the Glidescope&reg;, hemodynamic changes may be more pronounced and time to intubation longer compared with a lighted stylet [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/119\">",
"     119",
"    </a>",
"    ], but differences in these parameters are minimal when compared with Macintosh blade DL [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/132\">",
"     132",
"    </a>",
"    ] or flexible fiberoptic bronchoscopy (FFB) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/133\">",
"     133",
"    </a>",
"    ]. Complications occur infrequently with the Glidescope&reg; because structures are under direct visualization and little lifting force is used. Those reported include pharyngeal trauma from placement of the ETT [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/134,135\">",
"     134,135",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Pentax Airway Scope&reg; (AWS-S100) has a disposable L-shaped Lexan&reg; plastic blade with a video display integrated into the handle. The few studies with this device show excellent glottic exposure and less potential for dental trauma than a conventional Macintosh blade [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/136-138\">",
"     136-138",
"    </a>",
"    ]. One article describes its successful use intubating two failed airways [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/139\">",
"     139",
"    </a>",
"    ]. It may be useful in patients with cervical spine immobilization [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/140-142\">",
"     140-142",
"    </a>",
"    ], but there are no studies with ED patients.",
"   </p>",
"   <p>",
"    The King Vision&reg; is similar in shape to the Pentax AWS&reg;, but is designed to be a less expensive alternative to other video devices. It utilizes disposable J-shaped blades with a video chip and light source at the tip, with a reusable head unit containing a video screen. The blades come either with an ETT channel, to guide the ETT into the glottis, or without a channel if greater maneuverability is desired. Studies of the device are pending.",
"   </p>",
"   <p>",
"    The McGrath&reg; Series 5 Video Laryngoscope uses a screen mounted on the handle. In contrast to the Pentax AWS&reg;, the McGrath&reg; has a smaller profile, slightly different blade shape, and the capacity for sliding the CameraStick&trade; along the handle to accommodate different blade lengths for different sized patients. The McGrath&reg; gives excellent glottic exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/143\">",
"     143",
"    </a>",
"    ], and several observational and randomized studies describe its successful use in difficult and failed airways [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/115,144,145\">",
"     115,144,145",
"    </a>",
"    ]. In a trial of 93 elective surgery patients with an anticipated difficult airway randomly assigned to intubation using a flexible endoscope or the McGrath&reg; Series 5 Video Laryngoscope, no statistically significant difference was found between groups in time to intubation or the rate of successful intubation on the first attempt [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/146\">",
"     146",
"    </a>",
"    ]. These patients were intubated in a sniffing position while sedated but spontaneously breathing, so the results may not apply to patients intubated using rapid sequence intubation or requiring cervical spine immobilization. The McGrath&reg; MAC is similar to the Series 5 but has a standard Macintosh blade shape that allows direct laryngoscopy in addition to video laryngoscopy. There are no trials in ED patients of either McGrath&reg; video laryngoscope.",
"   </p>",
"   <p>",
"    In contrast to most other video laryngoscopes, the Storz CMAC video laryngoscope uses a standard Macintosh or Miller blade with a CMOS video chip affixed near the distal tip. The image is displayed on a simple external monitor. Laryngoscopy can be performed in standard fashion, with a tongue sweep and normal configuration of the ETT and stylet, or can be used in the midline, like the Glidescope. Potential advantages over a conventional Macintosh blade are related to the increased angle of view. Anterior vocal cords are visible on the screen that cannot be seen using direct laryngoscopy. In addition, the screen allows assistants to see the airway so they can aid in external laryngeal manipulation for improved view of the glottis.",
"   </p>",
"   <p>",
"    Observational and randomized trials suggest that the Storz Video Laryngoscope&reg; provides better glottic views and higher first pass success rates for intubation than direct laryngoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/111,147,148\">",
"     111,147,148",
"    </a>",
"    ]. In a small randomized trial, intubation of morbidly obese patients was easier using the Storz V-Mac than two other video laryngoscopes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/149\">",
"     149",
"    </a>",
"    ]. In another randomized trial of 130 patients with anticipated airway difficulty (Mallampati score &ge;3) undergoing elective surgery, intubation using the Storz CMAC was faster and first-pass success rates higher compared to intubation performed with the McGrath video laryngoscope [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/150\">",
"     150",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Optical laryngoscopes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optical laryngoscopes use lenses to provide a view of the anterior glottis not possible with direct laryngoscopy (DL). Although image quality is inferior to that of video laryngoscopes, optical laryngoscopes are an inexpensive, durable, and portable tool for difficult airway management. Two examples are the Truview&reg; laryngoscope (",
"    <a class=\"graphic graphic_picture graphicRef82250 \" href=\"UTD.htm?32/4/32847\">",
"     picture 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef62179 \" href=\"UTD.htm?5/63/6131\">",
"     picture 9",
"    </a>",
"    ) and the Airtraq&reg; optical laryngoscope (",
"    <a class=\"graphic graphic_picture graphicRef72818 \" href=\"UTD.htm?14/32/14863\">",
"     picture 10",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The Truview&reg; EVO has an angled laryngoscope blade with an affixed eyepiece and oxygen insufflation port to keep the optical lens clear of secretions or blood. The eyepiece and lens assembly allows the intubator to see 42 degrees anterior to the axis of the blade, enabling visualization of the glottis with less lifting force and improved exposure compared with a Macintosh laryngoscope [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/151,152\">",
"     151,152",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Airtraq&reg; is a unique optical laryngoscope with an L-shape, similar to the blade of the Pentax AWS&reg; that allows glottic visualization with the head and neck in a neutral position. It is a single-use device, simply constructed and inexpensive.",
"   </p>",
"   <p>",
"    A meta-analysis of 12 small randomized trials involving 1061 patients that compared the Airtraq&reg; to a standard Macintosh laryngoscope found that the Airtraq&reg; reduced the time required for intubation (-15 seconds, 95% CI -25- -4), increased first pass intubation success rates among novice airway managers (RR 1.25, CI 1.05-1.49), and reduced the incidence of esophageal intubation (RR 0.12, 95% CI 0.03-0.48) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/153\">",
"     153",
"    </a>",
"    ]. Individual studies noted that use of the Airtraq&reg; led to reduced cervical spine motion and less change in heart rate compared with DL using a Macintosh laryngoscope [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/154-158\">",
"     154-158",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Airtraq&reg; has been used as a rescue device for difficult airways and in one small randomized controlled trial outperformed DL using a Macintosh laryngoscope in patients with preoperatively defined difficult airway features [",
"    <a class=\"abstract\" href=\"UTD.htm?24/55/25466/abstract/159\">",
"     159",
"    </a>",
"    ]. For supervising or teaching purposes, a battery-powered camera and monitor can be attached.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SURGICAL AIRWAY DEVICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In emergency medicine, a surgical airway generally involves performing a cricothyrotomy in order to place a cuffed ETT in the trachea. This is most often accomplished using either an \"open\" or a percutaneous technique. Cricothyrotomy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=see_link\">",
"     \"Emergent surgical cricothyrotomy (cricothyroidotomy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of airway devices have been developed that enable improved management of difficult airways compared with direct laryngoscopy. The full impact of these devices on the concept of the difficult and failed airway is yet to be fully defined. The following points about these devices bear mentioning:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extraglottic devices establish an airway for oxygenation and ventilation without traversing the glottis, and are critical tools for the management of difficult and failed airways. The most commonly used extraglottic devices are the Laryngeal Mask Airway&trade; (LMA&trade;), Combitube&trade;, and laryngeal tubes. We recommend that clinicians responsible for airway management be familiar with at least one such device. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Extraglottic devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The endotracheal tube introducer (ie, gum elastic bougie) is an effective, inexpensive, easy-to-use adjunct to difficult airway management. We recommend that these be available in every emergency department. Two tactile sensations confirm correct placement in the trachea: the feeling of vibrations or \"clicks\" as the tip of the stylet is advanced over the tracheal rings and resistance to further insertion once the introducer reaches a smaller airway branch. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Endotracheal tube introducers (gum elastic bougie)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optical stylets (OS) incorporate a fiberoptic or video viewing element into the distal end of a metal stylet. The stylet can be rigid, semirigid, or directable. The viewing element effectively moves the intubator's view from outside the mouth to the tip of the OS and closer to the glottis, making it useful in patients with a difficult airway. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Optical stylets'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The flexible endoscope (FE) is essentially a flexible and directable stylet that can be used for airway management when difficult intubation is predicted, time is available, and neuromuscular paralysis is best avoided. Intubation using a FE is generally not performed in patients who require immediate establishment of an airway. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Flexible endoscope'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Video laryngoscopes are highly effective tools that can help maximize first-pass intubation success in both routine and difficult airway scenarios. Video laryngoscopes provide superior views of the glottis compared with direct laryngoscopy, and cause minimal movement of the cervical spine. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Video laryngoscopes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Murphy, M, Walls, RM. Identification of the Difficult and Failed Airway. In: Manual of Emergency Airway Management, 3rd, Walls, R, Murphy, MF (Eds), Lippincott, Williams and Wilkins, Philadelphia 2008. p.81.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/2\">",
"      Sagarin MJ, Barton ED, Chng YM, et al. Airway management by US and Canadian emergency medicine residents: a multicenter analysis of more than 6,000 endotracheal intubation attempts. Ann Emerg Med 2005; 46:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/3\">",
"      Bair AE, Laurin EG, Schmitt BJ. An assessment of a tracheal tube introducer as an endotracheal tube placement confirmation device. Am J Emerg Med 2005; 23:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/4\">",
"      Kidd JF, Dyson A, Latto IP. Successful difficult intubation. Use of the gum elastic bougie. Anaesthesia 1988; 43:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/5\">",
"      Gataure PS, Vaughan RS, Latto IP. Simulated difficult intubation. Comparison of the gum elastic bougie and the stylet. Anaesthesia 1996; 51:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/6\">",
"      Detave M, Shiniara M, Leborgne JM. [Use of Eschmann's gum elastic bougie in difficult orotracheal intubation, an audit over eight years of clinical practice]. Ann Fr Anesth Reanim 2008; 27:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/7\">",
"      Martin LD, Mhyre JM, Shanks AM, et al. 3,423 emergency tracheal intubations at a university hospital: airway outcomes and complications. Anesthesiology 2011; 114:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/8\">",
"      Le DH, Reed DB, Weinstein G, et al. Paramedic use of endotracheal tube introducers for the difficult airway. Prehosp Emerg Care 2001; 5:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/9\">",
"      Phelan MP, Moscati R, D'Aprix T, Miller G. Paramedic use of the endotracheal tube introducer in a difficult airway model. Prehosp Emerg Care 2003; 7:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/10\">",
"      Jabre P, Combes X, Leroux B, et al. Use of gum elastic bougie for prehospital difficult intubation. Am J Emerg Med 2005; 23:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/11\">",
"      Kadry T, Harvey M, Wallace M, Imrie J. Frova intubating catheter position can be determined with aspirating oesophageal detection device. Emerg Med Australas 2007; 19:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/12\">",
"      Kadry M, Popat M. Pharyngeal wall perforation--an unusual complication of blind intubation with a gum elastic bougie. Anaesthesia 1999; 54:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/13\">",
"      Evans A, Morris S, Petterson J, Hall JE. A comparison of the Seeing Optical Stylet and the gum elastic bougie in simulated difficult tracheal intubation: a manikin study. Anaesthesia 2006; 61:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/14\">",
"      Koyama Y, Inagawa G, Miyashita T, et al. Comparison of the Airway Scope, gum elastic bougie and fibreoptic bronchoscope in simulated difficult tracheal intubation: a manikin study. Anaesthesia 2007; 62:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/15\">",
"      Soh CR, Kong CF, Kong CS, et al. Tracheal intubation by novice staff: the direct vision laryngoscope or the lighted stylet (Trachlight)? Emerg Med J 2002; 19:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/16\">",
"      Margolis GS, Menegazzi J, Abdlehak M, Delbridge TR. The efficacy of a standard training program for transillumination-guided endotracheal intubation. Acad Emerg Med 1996; 3:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/17\">",
"      Wik L, Naess AC, Steen PA. Intubation with laryngoscope versus transillumination performed by paramedic students on manikins and cadavers. Resuscitation 1997; 33:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/18\">",
"      Hung OR, Pytka S, Morris I, et al. Clinical trial of a new lightwand device (Trachlight) to intubate the trachea. Anesthesiology 1995; 83:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/19\">",
"      Berns SD, Patel RI, Chamberlain JM. Oral intubation using a lighted stylet vs direct laryngoscopy in older children with cervical immobilization. Acad Emerg Med 1996; 3:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/20\">",
"      Tsutsui T, Setoyama K. [A clinical evaluation of blind orotracheal intubation using Trachlight in 511 patients]. Masui 2001; 50:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/21\">",
"      Hung OR, Pytka S, Morris I, et al. Lightwand intubation: II--Clinical trial of a new lightwand for tracheal intubation in patients with difficult airways. Can J Anaesth 1995; 42:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/22\">",
"      Kanaide M, Fukusaki M, Tamura S, et al. Hemodynamic and catecholamine responses during tracheal intubation using a lightwand device (Trachlight) in elderly patients with hypertension. J Anesth 2003; 17:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/23\">",
"      Rhee KY, Lee JR, Kim J, et al. A comparison of lighted stylet (Surch-Lite) and direct laryngoscopic intubation in patients with high Mallampati scores. Anesth Analg 2009; 108:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/24\">",
"      Amornyotin S, Sanansilp V, Amorntien V, Tirawat P. Effectiveness of lightwand (Trachlight) intubation by 1st year anesthesia residents. J Med Assoc Thai 2002; 85 Suppl 3:S963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/25\">",
"      Konishi A, Kikuchi K, Sasui M. [Cervival spine movement during light-guided orotracheal intubation with lightwand stylet (Trachlight)]. Masui 1998; 47:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/26\">",
"      Turkstra TP, Pelz DM, Shaikh AA, Craen RA. Cervical spine motion: a fluoroscopic comparison of Shikani Optical Stylet vs Macintosh laryngoscope. Can J Anaesth 2007; 54:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/27\">",
"      Turkstra TP, Craen RA, Pelz DM, Gelb AW. Cervical spine motion: a fluoroscopic comparison during intubation with lighted stylet, GlideScope, and Macintosh laryngoscope. Anesth Analg 2005; 101:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/28\">",
"      Hirabayashi Y, Hiruta M, Kawakami T, et al. Effects of lightwand (Trachlight) compared with direct laryngoscopy on circulatory responses to tracheal intubation. Br J Anaesth 1998; 81:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/29\">",
"      Kihara S, Brimacombe J, Yaguchi Y, et al. Hemodynamic responses among three tracheal intubation devices in normotensive and hypertensive patients. Anesth Analg 2003; 96:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/30\">",
"      Favaro R, Tordiglione P, Di Lascio F, et al. Effective nasotracheal intubation using a modified transillumination technique. Can J Anaesth 2002; 49:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/31\">",
"      Fan KH, Hung OR, Agro F. A comparative study of tracheal intubation using an intubating laryngeal mask (Fastrach) alone or together with a lightwand (Trachlight). J Clin Anesth 2000; 12:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/32\">",
"      Agr&ograve; F, Hung OR, Cataldo R, et al. Lightwand intubation using the Trachlight: a brief review of current knowledge. Can J Anaesth 2001; 48:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/33\">",
"      Hung OR, Stewart RD. Lightwand intubation: I--a new lightwand device. Can J Anaesth 1995; 42:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/34\">",
"      Phua DS, Mah CL, Wang CF. The Shikani optical stylet as an alternative to the GlideScope&reg; videolaryngoscope in simulated difficult intubations--a randomised controlled trial. Anaesthesia 2012; 67:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/35\">",
"      Kok T, George RB, McKeen D, et al. Effectiveness and safety of the Levitan FPS Scope&trade; for tracheal intubation under general anesthesia with a simulated difficult airway. Can J Anaesth 2012; 59:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/36\">",
"      Kimura A, Yamakage M, Chen X, et al. Use of the fibreoptic stylet scope (Styletscope) reduces the hemodynamic response to intubation in normotensive and hypertensive patients. Can J Anaesth 2001; 48:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/37\">",
"      Gravenstein D, Liem EB, Bjoraker DG. Alternative management techniques for the difficult airway: optical stylets. Curr Opin Anaesthesiol 2004; 17:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/38\">",
"      Levitan RM, Kush S, Hollander JE. Devices for difficult airway management in academic emergency departments: results of a national survey. Ann Emerg Med 1999; 33:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/39\">",
"      Birmingham B, Mentzer SJ, Body SC. Laryngeal mask airway for therapeutic fiberoptic bronchoscopic procedures. J Cardiothorac Vasc Anesth 1996; 10:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/40\">",
"      Benumof JL. A new technique of fiberoptic intubation through a standard LMA. Anesthesiology 2001; 95:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/41\">",
"      Ianchulev SA. Through-the-LMA fiberoptic intubation of the trachea in a patient with an unexpected difficult airway. Anesth Analg 2005; 101:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/42\">",
"      J&ouml;hr M, Berger TM. Fiberoptic intubation through the laryngeal mask airway (LMA) as a standardized procedure. Paediatr Anaesth 2004; 14:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/43\">",
"      Hershey MD, Hannenberg AA. Gastric distention and rupture from oxygen insufflation during fiberoptic intubation. Anesthesiology 1996; 85:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/44\">",
"      Afilalo M, Guttman A, Stern E, et al. Fiberoptic intubation in the emergency department: a case series. J Emerg Med 1993; 11:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/45\">",
"      Mlinek EJ Jr, Clinton JE, Plummer D, Ruiz E. Fiberoptic intubation in the emergency department. Ann Emerg Med 1990; 19:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/46\">",
"      Schafermeyer RW. Fiberoptic laryngoscopy in the emergency department. Am J Emerg Med 1984; 2:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/47\">",
"      Blanda M, Gallo UE. Emergency airway management. Emerg Med Clin North Am 2003; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/48\">",
"      Hamilton PH, Kang JJ. Emergency airway management. Mt Sinai J Med 1997; 64:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/49\">",
"      Russi CS, Miller L, Hartley MJ. A comparison of the King-LT to endotracheal intubation and Combitube in a simulated difficult airway. Prehosp Emerg Care 2008; 12:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/50\">",
"      Asai T, Shingu K. The laryngeal tube. Br J Anaesth 2005; 95:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/51\">",
"      Calkins MD, Robinson TD. Combat trauma airway management: endotracheal intubation versus laryngeal mask airway versus combitube use by Navy SEAL and Reconnaissance combat corpsmen. J Trauma 1999; 46:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/52\">",
"      Fukutome T, Amaha K, Nakazawa K, et al. Tracheal intubation through the intubating laryngeal mask airway (LMA-Fastrach) in patients with difficult airways. Anaesth Intensive Care 1998; 26:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/53\">",
"      Parmet JL, Colonna-Romano P, Horrow JC, et al. The laryngeal mask airway reliably provides rescue ventilation in cases of unanticipated difficult tracheal intubation along with difficult mask ventilation. Anesth Analg 1998; 87:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/54\">",
"      Jones JR. Laryngeal mask airway: an alternative for the difficult airway. AANA J 1995; 63:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/55\">",
"      Asai T, Appadurai I. LMA for failed intubation. Can J Anaesth 1993; 40:802; author reply 803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/56\">",
"      Levy DM. LMA for failed intubation. Can J Anaesth 1993; 40:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/57\">",
"      Brimacombe J, Berry A. LMA for failed intubation. Can J Anaesth 1993; 40:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/58\">",
"      Rosenblatt WH, Murphy M. The intubating laryngeal mask: use of a new ventilating-intubating device in the emergency department. Ann Emerg Med 1999; 33:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/59\">",
"      Levitan RM, Ochroch EA, Stuart S, Hollander JE. Use of the intubating laryngeal mask airway by medical and nonmedical personnel. Am J Emerg Med 2000; 18:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/60\">",
"      Foley LJ, Ochroch EA. Bridges to establish an emergency airway and alternate intubating techniques. Crit Care Clin 2000; 16:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/61\">",
"      Stanwood PL. The laryngeal mask airway and the emergency airway. AANA J 1997; 65:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/62\">",
"      Young B. The intubating laryngeal-mask airway may be an ideal device for airway control in the rural trauma patient. Am J Emerg Med 2003; 21:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/63\">",
"      Ferson DZ, Rosenblatt WH, Johansen MJ, et al. Use of the intubating LMA-Fastrach in 254 patients with difficult-to-manage airways. Anesthesiology 2001; 95:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/64\">",
"      Wakeling HG, Bagwell A. The intubating laryngeal mask (ILMA) in an emergency failed intubation. Anaesthesia 1999; 54:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/65\">",
"      Joo HS, Rose DK. The intubating laryngeal mask airway with and without fiberoptic guidance. Anesth Analg 1999; 88:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/66\">",
"      Asai T, Morris S. The laryngeal mask airway: its features, effects and role. Can J Anaesth 1994; 41:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/67\">",
"      Gatward JJ, Cook TM, Seller C, et al. Evaluation of the size 4 i-gel airway in one hundred non-paralysed patients. Anaesthesia 2008; 63:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/68\">",
"      Theiler LG, Kleine-Brueggeney M, Kaiser D, et al. Crossover comparison of the laryngeal mask supreme and the i-gel in simulated difficult airway scenario in anesthetized patients. Anesthesiology 2009; 111:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/69\">",
"      Theiler L, Gutzmann M, Kleine-Brueggeney M, et al. i-gel&trade; supraglottic airway in clinical practice: a prospective observational multicentre study. Br J Anaesth 2012; 109:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/70\">",
"      Halwagi AE, Massicotte N, Lallo A, et al. Tracheal intubation through the I-gel&trade; supraglottic airway versus the LMA Fastrach&trade;: a randomized controlled trial. Anesth Analg 2012; 114:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/71\">",
"      Law J, Bair A, Capra J, et al. Characterization of airway device cuff volumes at simulated altitude. Aviat Space Environ Med 2011; 82:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/72\">",
"      McQuibban GA. LMA-FasTrach. Can J Anaesth 1998; 45:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/73\">",
"      Pollack CV Jr. The laryngeal mask airway: a comprehensive review for the Emergency Physician. J Emerg Med 2001; 20:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/74\">",
"      Okuda K, Inagawa G, Miwa T, Hiroki K. Influence of head and neck position on cuff position and oropharyngeal sealing pressure with the laryngeal mask airway in children. Br J Anaesth 2001; 86:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/75\">",
"      Keller C, Brimacombe J. The influence of head and neck position on oropharyngeal leak pressure and cuff position with the flexible and the standard laryngeal mask airway. Anesth Analg 1999; 88:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/76\">",
"      Brimacombe J, Berry A. Leak reduction with the LMA. Can J Anaesth 1996; 43:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/77\">",
"      Ramachandran SK, Mathis MR, Tremper KK, et al. Predictors and clinical outcomes from failed Laryngeal Mask Airway Unique&trade;: a study of 15,795 patients. Anesthesiology 2012; 116:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/78\">",
"      Teoh WH, Lim Y. Comparison of the single use and reusable intubating laryngeal mask airway. Anaesthesia 2007; 62:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/79\">",
"      Turan A, Kaya G, Koyuncu O, et al. Comparison of the laryngeal mask (LMA) and laryngeal tube (LT) with the new perilaryngeal airway (CobraPLA) in short surgical procedures. Eur J Anaesthesiol 2006; 23:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/80\">",
"      Kurola J, Pere P, Niemi-Murola L, et al. Comparison of airway management with the intubating laryngeal mask, laryngeal tube and CobraPLA by paramedical students in anaesthetized patients. Acta Anaesthesiol Scand 2006; 50:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/81\">",
"      Genzwuerker HV, Fritz A, Hinkelbein J, et al. Prospective, randomized comparison of laryngeal tube and laryngeal mask airway in pediatric patients. Paediatr Anaesth 2006; 16:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/82\">",
"      Klaver NS, Kuizenga K, Ballast A, Fidler V. A comparison of the clinical use of the Laryngeal Tube S and the ProSeal Laryngeal Mask Airway by first-month anaesthesia residents in anaesthetised patients. Anaesthesia 2007; 62:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/83\">",
"      Yildiz TS, Solak M, Toker K. Comparison of laryngeal tube with laryngeal mask airway in anaesthetized and paralysed patients. Eur J Anaesthesiol 2007; 24:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/84\">",
"      Dhonneur G, Ndoko SK, Yavchitz A, et al. Tracheal intubation of morbidly obese patients: LMA CTrach vs direct laryngoscopy. Br J Anaesth 2006; 97:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/85\">",
"      Agro F, Frass M, Benumof JL, Krafft P. Current status of the Combitube: a review of the literature. J Clin Anesth 2002; 14:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/86\">",
"      Lefran&ccedil;ois DP, Dufour DG. Use of the esophageal tracheal combitube by basic emergency medical technicians. Resuscitation 2002; 52:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/87\">",
"      Davis DP, Valentine C, Ochs M, et al. The Combitube as a salvage airway device for paramedic rapid sequence intubation. Ann Emerg Med 2003; 42:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/88\">",
"      Rabitsch W, Schellongowski P, Staudinger T, et al. Comparison of a conventional tracheal airway with the Combitube in an urban emergency medical services system run by physicians. Resuscitation 2003; 57:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/89\">",
"      Blostein PA, Koestner AJ, Hoak S. Failed rapid sequence intubation in trauma patients: esophageal tracheal combitube is a useful adjunct. J Trauma 1998; 44:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/90\">",
"      Mercer M. The role of the Combitube in airway management. Anaesthesia 2000; 55:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/91\">",
"      Gaitini LA, Vaida SJ, Agro F. The Esophageal-Tracheal Combitube. Anesthesiol Clin North America 2002; 20:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/92\">",
"      Idris AH, Gabrielli A. Advances in airway management. Emerg Med Clin North Am 2002; 20:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/93\">",
"      Keller C, Brimacombe J, Boehler M, et al. The influence of cuff volume and anatomic location on pharyngeal, esophageal, and tracheal mucosal pressures with the esophageal tracheal combitube. Anesthesiology 2002; 96:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/94\">",
"      Shuster M, Nolan J, Barnes TA. Airway and ventilation management. Cardiol Clin 2002; 20:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/95\">",
"      Agr&ograve; F, Frass M, Benumof J, et al. The esophageal tracheal combitube as a non-invasive alternative to endotracheal intubation. A review. Minerva Anestesiol 2001; 67:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/96\">",
"      Mercer MH. An assessment of protection of the airway from aspiration of oropharyngeal contents using the Combitube airway. Resuscitation 2001; 51:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/97\">",
"      Urtubia RM, Gazmuri RR. Is the combitube traumatic? Anesthesiology 2003; 98:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/98\">",
"      Urtubia RM, C&aacute;rcamo CR, Montes JM. Complications following the use of the Combitube, tracheal tube and laryngeal mask airway. Anaesthesia 2000; 55:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/99\">",
"      Oczenski W, Krenn H, Dahaba AA, et al. Complications following the use of the Combitube, tracheal tube and laryngeal mask airway. Anaesthesia 1999; 54:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/100\">",
"      Moser MS. Piriform sinus perforation during esophageal-tracheal combitube placement. J Emerg Med 1999; 17:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/101\">",
"      Richards CF. Piriform sinus perforation during Esophageal-Tracheal Combitube placement. J Emerg Med 1998; 16:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/102\">",
"      Krafft P, Nikolic A, Frass M. Esophageal rupture associated with the use of the Combitube. Anesth Analg 1998; 87:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/103\">",
"      Krafft P, Frass M, Reed AP. Complications with the Combitube. Can J Anaesth 1998; 45:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/104\">",
"      Walz R, Bund M, Meier PN, Panning B. Esophageal rupture associated with the use of the Combitube. Anesth Analg 1998; 87:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/105\">",
"      V&eacute;zina D, Lessard MR, Bussi&egrave;res J, et al. Complications associated with the use of the Esophageal-Tracheal Combitube. Can J Anaesth 1998; 45:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/106\">",
"      Klein H, Williamson M, Sue-Ling HM, et al. Esophageal rupture associated with the use of the Combitube. Anesth Analg 1997; 85:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/107\">",
"      Guyette FX, Wang H, Cole JS. King airway use by air medical providers. Prehosp Emerg Care 2007; 11:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/108\">",
"      Russi CS, Wilcox CL, House HR. The laryngeal tube device: a simple and timely adjunct to airway management. Am J Emerg Med 2007; 25:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/109\">",
"      Winterhalter M, Kirchhoff K, Gr&ouml;schel W, et al. The laryngeal tube for difficult airway management: a prospective investigation in patients with pharyngeal and laryngeal tumours. Eur J Anaesthesiol 2005; 22:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/110\">",
"      Lutes M, Worman DJ. An unanticipated complication of a novel approach to airway management. J Emerg Med 2010; 38:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/111\">",
"      Sakles JC, Mosier J, Chiu S, et al. A comparison of the C-MAC video laryngoscope to the Macintosh direct laryngoscope for intubation in the emergency department. Ann Emerg Med 2012; 60:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/112\">",
"      Tremblay MH, Williams S, Robitaille A, Drolet P. Poor visualization during direct laryngoscopy and high upper lip bite test score are predictors of difficult intubation with the GlideScope videolaryngoscope. Anesth Analg 2008; 106:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/113\">",
"      Hsiao WT, Lin YH, Wu HS, Chen CL. Does a new videolaryngoscope (glidescope) provide better glottic exposure? Acta Anaesthesiol Taiwan 2005; 43:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/114\">",
"      Brown CA 3rd, Bair AE, Pallin DJ, et al. Improved glottic exposure with the Video Macintosh Laryngoscope in adult emergency department tracheal intubations. Ann Emerg Med 2010; 56:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/115\">",
"      Noppens RR, M&ouml;bus S, Heid F, et al. Evaluation of the McGrath Series 5 videolaryngoscope after failed direct laryngoscopy. Anaesthesia 2010; 65:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/116\">",
"      Piepho T, Fortmueller K, Heid FM, et al. Performance of the C-MAC video laryngoscope in patients after a limited glottic view using Macintosh laryngoscopy. Anaesthesia 2011; 66:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/117\">",
"      Griesdale DE, Liu D, McKinney J, Choi PT. Glidescope&reg; video-laryngoscopy versus direct laryngoscopy for endotracheal intubation: a systematic review and meta-analysis. Can J Anaesth 2012; 59:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/118\">",
"      Su YC, Chen CC, Lee YK, et al. Comparison of video laryngoscopes with direct laryngoscopy for tracheal intubation: a meta-analysis of randomised trials. Eur J Anaesthesiol 2011; 28:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/119\">",
"      Huang WT, Huang CY, Chung YT. Clinical comparisons between GlideScope video laryngoscope and Trachlight in simulated cervical spine instability. J Clin Anesth 2007; 19:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/120\">",
"      Robitaille A, Williams SR, Tremblay MH, et al. Cervical spine motion during tracheal intubation with manual in-line stabilization: direct laryngoscopy versus GlideScope videolaryngoscopy. Anesth Analg 2008; 106:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/121\">",
"      Kill C, Risse J, Wallot P, et al. Videolaryngoscopy with glidescope reduces cervical spine movement in patients with unsecured cervical spine. J Emerg Med 2013; 44:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/122\">",
"      Mosier J, Chiu S, Patanwala AE, Sakles JC. A Comparison of the GlideScope Video Laryngoscope to the C-MAC Video Laryngoscope for Intubation in the Emergency Department. Ann Emerg Med 2013; 61:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/123\">",
"      Jones PM, Turkstra TP, Armstrong KP, et al. Effect of stylet angulation and endotracheal tube camber on time to intubation with the GlideScope. Can J Anaesth 2007; 54:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/124\">",
"      Sakles JC, Kalin L. The effect of stylet choice on the success rate of intubation using the GlideScope video laryngoscope in the emergency department. Acad Emerg Med 2012; 19:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/125\">",
"      Turkstra TP, Harle CC, Armstrong KP, et al. The GlideScope-specific rigid stylet and standard malleable stylet are equally effective for GlideScope use. Can J Anaesth 2007; 54:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/126\">",
"      Sun DA, Warriner CB, Parsons DG, et al. The GlideScope Video Laryngoscope: randomized clinical trial in 200 patients. Br J Anaesth 2005; 94:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/127\">",
"      Cooper RM, Pacey JA, Bishop MJ, McCluskey SA. Early clinical experience with a new videolaryngoscope (GlideScope) in 728 patients. Can J Anaesth 2005; 52:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/128\">",
"      Lim Y, Yeo SW. A comparison of the GlideScope with the Macintosh laryngoscope for tracheal intubation in patients with simulated difficult airway. Anaesth Intensive Care 2005; 33:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/129\">",
"      Hirabayashi Y, Hakozaki T, Fujisawa K, et al. [GlideScope videolaryngoscope: a clinical assessment of its performance in 200 consecutive patients]. Masui 2007; 56:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/130\">",
"      Nouruzi-Sedeh P, Schumann M, Groeben H. Laryngoscopy via Macintosh blade versus GlideScope: success rate and time for endotracheal intubation in untrained medical personnel. Anesthesiology 2009; 110:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/131\">",
"      Aziz MF, Healy D, Kheterpal S, et al. Routine clinical practice effectiveness of the Glidescope in difficult airway management: an analysis of 2,004 Glidescope intubations, complications, and failures from two institutions. Anesthesiology 2011; 114:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/132\">",
"      Xue FS, Zhang GH, Li XY, et al. Comparison of hemodynamic responses to orotracheal intubation with the GlideScope videolaryngoscope and the Macintosh direct laryngoscope. J Clin Anesth 2007; 19:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/133\">",
"      Xue FS, Zhang GH, Li XY, et al. Comparison of haemodynamic responses to orotracheal intubation with GlideScope videolaryngoscope and fibreoptic bronchoscope. Eur J Anaesthesiol 2006; 23:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/134\">",
"      Cooper RM. Complications associated with the use of the GlideScope videolaryngoscope. Can J Anaesth 2007; 54:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/135\">",
"      Vincent RD Jr, Wimberly MP, Brockwell RC, Magnuson JS. Soft palate perforation during orotracheal intubation facilitated by the GlideScope videolaryngoscope. J Clin Anesth 2007; 19:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/136\">",
"      Asai T, Enomoto Y, Shimizu K, et al. The Pentax-AWS video-laryngoscope: the first experience in one hundred patients. Anesth Analg 2008; 106:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/137\">",
"      Asai T, Liu EH, Matsumoto S, et al. Use of the Pentax-AWS in 293 patients with difficult airways. Anesthesiology 2009; 110:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/138\">",
"      Komatsu R, Kamata K, Hamada K, et al. Airway scope and StyletScope for tracheal intubation in a simulated difficult airway. Anesth Analg 2009; 108:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/139\">",
"      Asai T, Enomoto Y, Shingu K, Okuda Y. [Pentax AWS airway scope]. Masui 2007; 56:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/140\">",
"      Liu EH, Goy RW, Tan BH, Asai T. Tracheal intubation with videolaryngoscopes in patients with cervical spine immobilization: a randomized trial of the Airway Scope and the GlideScope. Br J Anaesth 2009; 103:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/141\">",
"      Malik MA, Subramaniam R, Churasia S, et al. Tracheal intubation in patients with cervical spine immobilization: a comparison of the Airwayscope, LMA CTrach, and the Macintosh laryngoscopes. Br J Anaesth 2009; 102:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/142\">",
"      Aoi Y, Inagawa G, Nakamura K, et al. Airway scope versus macintosh laryngoscope in patients with simulated limitation of neck movements. J Trauma 2010; 69:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/143\">",
"      Shippey B, Ray D, McKeown D. Case series: the McGrath videolaryngoscope--an initial clinical evaluation. Can J Anaesth 2007; 54:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/144\">",
"      Shippey B, Ray D, McKeown D. Use of the McGrath videolaryngoscope in the management of difficult and failed tracheal intubation. Br J Anaesth 2008; 100:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/145\">",
"      Taylor AM, Peck M, Launcelott S, et al. The McGrath&reg; Series 5 videolaryngoscope vs the Macintosh laryngoscope: a randomised, controlled trial in patients with a simulated difficult airway. Anaesthesia 2013; 68:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/146\">",
"      Rosenstock CV, Th&oslash;gersen B, Afshari A, et al. Awake fiberoptic or awake video laryngoscopic tracheal intubation in patients with anticipated difficult airway management: a randomized clinical trial. Anesthesiology 2012; 116:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/147\">",
"      Kaplan MB, Ward DS, Berci G. A new video laryngoscope-an aid to intubation and teaching. J Clin Anesth 2002; 14:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/148\">",
"      Aziz MF, Dillman D, Fu R, Brambrink AM. Comparative effectiveness of the C-MAC video laryngoscope versus direct laryngoscopy in the setting of the predicted difficult airway. Anesthesiology 2012; 116:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/149\">",
"      Maassen R, Lee R, Hermans B, et al. A comparison of three videolaryngoscopes: the Macintosh laryngoscope blade reduces, but does not replace, routine stylet use for intubation in morbidly obese patients. Anesth Analg 2009; 109:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/150\">",
"      Ng I, Hill AL, Williams DL, et al. Randomized controlled trial comparing the McGrath videolaryngoscope with the C-MAC videolaryngoscope in intubating adult patients with potential difficult airways. Br J Anaesth 2012; 109:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/151\">",
"      Lieberman, N, Hakim, AR, Lemberg, L, et, al. Trueview&reg; Blade Improves Laryngeal View When Compared to Macintosh Blade. Anesthesiology 2003; 99:A565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/152\">",
"      Khan, Y, Jain, S, Khan, RM, et, al. Use of Macintosh, Trueview, and Airtraq Laryngoscopes for Intubation of Immobilized Manikins Head. Anesthesiology 2007; 107:A588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/153\">",
"      Lu Y, Jiang H, Zhu YS. Airtraq laryngoscope versus conventional Macintosh laryngoscope: a systematic review and meta-analysis. Anaesthesia 2011; 66:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/154\">",
"      Maharaj CH, O'Croinin D, Curley G, et al. A comparison of tracheal intubation using the Airtraq or the Macintosh laryngoscope in routine airway management: A randomised, controlled clinical trial. Anaesthesia 2006; 61:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/155\">",
"      Maharaj CH, Costello JF, McDonnell JG, et al. The Airtraq as a rescue airway device following failed direct laryngoscopy: a case series. Anaesthesia 2007; 62:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/156\">",
"      Turkstra TP, Pelz DM, Jones PM. Cervical spine motion: a fluoroscopic comparison of the AirTraq Laryngoscope versus the Macintosh laryngoscope. Anesthesiology 2009; 111:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/157\">",
"      Hirabayashi Y, Fujita A, Seo N, Sugimoto H. A comparison of cervical spine movement during laryngoscopy using the Airtraq or Macintosh laryngoscopes. Anaesthesia 2008; 63:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/158\">",
"      Di Marco P, Scattoni L, Spinoglio A, et al. Learning curves of the Airtraq and the Macintosh laryngoscopes for tracheal intubation by novice laryngoscopists: a clinical study. Anesth Analg 2011; 112:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/55/25466/abstract/159\">",
"      Maharaj CH, Costello JF, Harte BH, Laffey JG. Evaluation of the Airtraq and Macintosh laryngoscopes in patients at increased risk for difficult tracheal intubation. Anaesthesia 2008; 63:182.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 269 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-B869A8C837-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_55_25466=[""].join("\n");
var outline_f24_55_25466=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STYLETS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Endotracheal tube introducers (gum elastic bougie)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Lighted stylets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Optical stylets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Flexible endoscope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EXTRAGLOTTIC DEVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laryngeal mask airways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Combitube&trade;",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Laryngeal and pharyngeal tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SCOPES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Video laryngoscopes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Optical laryngoscopes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SURGICAL AIRWAY DEVICES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/269\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/269|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/30/20974\" title=\"figure 1\">",
"      Frova introducer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/24/20864\" title=\"figure 2\">",
"      SunMed bougie",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/2/34863\" title=\"figure 3\">",
"      Cormack Lehane laryngoscopy grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/52/40783\" title=\"figure 4\">",
"      King LT anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/17/11551\" title=\"figure 5\">",
"      McGrath video laryngoscope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/269|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/35/10802\" title=\"picture 1\">",
"      Bonfils fiberoptic stylts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/20/39247\" title=\"picture 2\">",
"      Standard LMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/43/22207\" title=\"picture 3\">",
"      Fastrach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/35/33343\" title=\"picture 4\">",
"      King LT device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/18/12576\" title=\"picture 5\">",
"      GlideScope Cobalt video laryngoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/62/33775\" title=\"picture 6\">",
"      Pentax Airway Scope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/3/27700\" title=\"picture 7\">",
"      Storz C Mac video laryngoscope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/4/32847\" title=\"picture 8\">",
"      TruViewEV01",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/63/6131\" title=\"picture 9\">",
"      Truview detail photo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/32/14863\" title=\"picture 10\">",
"      Airtraq device",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4905?source=related_link\">",
"      Emergent surgical cricothyrotomy (cricothyroidotomy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38135?source=related_link\">",
"      Flexible bronchoscopy: Indications and contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18552?source=related_link\">",
"      The difficult airway in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=related_link\">",
"      The difficult pediatric airway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18228?source=related_link\">",
"      The failed airway in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_55_25467="Bulb syringe PI";
var content_f24_55_25467=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F67982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F67982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Instructions on using a bulb syringe",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Nasal congestion from a cold can make it difficult for a young infant to breathe while eating. Mucus can be removed from the infant's nose with a bulb syringe.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Before using a bulb syringe, saline nose drops can be used to thin the mucus. Saline nose drops can be purchased in most pharmacies, or can be made at home by adding 1/4 teaspoon salt to 8 ounces (1 cup) of warm (not hot) water. Stir to dissolve the salt, and store the solution for up to 1 week in a clean container with a cover.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Place the infant on his or her back. Using a clean nose dropper, place 1 to 2 drops of saline solution in each nostril. Wait a short period.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Squeeze and hold the bulb syringe to remove the air. Gently insert the tip of the bulb syringe into one nostril, and release the bulb. The suction will draw mucus out of the nostril into the bulb.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Squeeze the mucus out of the bulb into a tissue.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Repeat suction process several times in each nostril until most mucus is removed.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Wash the dropper and bulb syringe in warm, soapy water. Rinse well, and squeeze to remove any water.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The bulb syringe can be used two to three times per day as needed to remove mucus. It is best to do this before feeding; the saline and suction process can cause vomiting after feeding.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Information from file://www.cincinnatichildrens.org/health/info/newborn/home/suction.htm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_55_25467=[""].join("\n");
var outline_f24_55_25467=null;
var title_f24_55_25468="HCG postmiscarriage";
var content_f24_55_25468=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Percent decline in HCG levels following spontaneous pregnancy loss, based on the initial measured level",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Initial HCG level (mIU/mL)",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"3\">",
"       Percent decline in HCG*",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Mean days until HCG &lt;5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Day 2",
"      </td>",
"      <td class=\"subtitle2\">",
"       Day 7",
"      </td>",
"      <td class=\"subtitle2\">",
"       Day 14",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       250",
"      </td>",
"      <td>",
"       70 (36, 21)",
"      </td>",
"      <td>",
"       93 (72, 60)",
"      </td>",
"      <td>",
"       100 (87, 75)",
"      </td>",
"      <td>",
"       12",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       500",
"      </td>",
"      <td>",
"       71 (39, 24)",
"      </td>",
"      <td>",
"       94 (77, 68)",
"      </td>",
"      <td>",
"       100 (92, 94)",
"      </td>",
"      <td>",
"       13",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1000",
"      </td>",
"      <td>",
"       72 (42, 28)",
"      </td>",
"      <td>",
"       95 (82, 74)",
"      </td>",
"      <td>",
"       100 (95, 90)",
"      </td>",
"      <td>",
"       14",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1500",
"      </td>",
"      <td>",
"       73 (43, 30)",
"      </td>",
"      <td>",
"       96 (84, 77)",
"      </td>",
"      <td>",
"       100 (96, 92)",
"      </td>",
"      <td>",
"       15",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2000",
"      </td>",
"      <td>",
"       74 (44, 31)",
"      </td>",
"      <td>",
"       96 (85, 79)",
"      </td>",
"      <td>",
"       100 (97, 93)",
"      </td>",
"      <td>",
"       15",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2500",
"      </td>",
"      <td>",
"       74 (45, 32)",
"      </td>",
"      <td>",
"       96 (86, 80)",
"      </td>",
"      <td>",
"       100 (97, 94)",
"      </td>",
"      <td>",
"       15",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3000",
"      </td>",
"      <td>",
"       74 (46, 33)",
"      </td>",
"      <td>",
"       96 (87, 81)",
"      </td>",
"      <td>",
"       100 (97, 95)",
"      </td>",
"      <td>",
"       15",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4000",
"      </td>",
"      <td>",
"       75 (47, 34)",
"      </td>",
"      <td>",
"       97 (88, 83)",
"      </td>",
"      <td>",
"       100 (98, 96)",
"      </td>",
"      <td>",
"       15",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5000",
"      </td>",
"      <td>",
"       75 (47, 35)",
"      </td>",
"      <td>",
"       97 (89, 84)",
"      </td>",
"      <td>",
"       100 (98, 96)",
"      </td>",
"      <td>",
"       16",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Expressed as mean percent decline with 90",
"     <sup>",
"      th",
"     </sup>",
"     and 95",
"     <sup>",
"      th",
"     </sup>",
"     percentiles in parentheses.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Barnhart K, Sammel MD, Chung K, et al. Decline of serum human chorionic gonadotropin and spontaneous complete abortion: defining the normal curve. Obstet Gynecol 2004; 104:975. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_55_25468=[""].join("\n");
var outline_f24_55_25468=null;
var title_f24_55_25469="Atorvastatin vs PTCA ischemia";
var content_f24_55_25469=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atovastatin may reduce ischemic events compared with angioplasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 278px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The AVERT trial randomly assigned 341 patients with angina and one or two vessel coronary disease to aggressive lipid lowering therapy with atorvastatin or angioplasty. Compared to angioplasty, atorvastatin therapy was associated with a nonsignificant trend toward fewer cardiac events (13 versus 21 percent).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Pitt, B, Waters, D, Brown, WV, et al, N Engl J Med 1999; 341:70.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_55_25469=[""].join("\n");
var outline_f24_55_25469=null;
var title_f24_55_25470="Calcitonin BMD";
var content_f24_55_25470=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lumbar spine bone mineral density, mean percentage change from baseline (&plusmn; SEM)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 443px; height: 246px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Number of participants with at least 1 post-baseline evaluation for placebo, 100 IU, 200 IU and 400 IU; n = 268, 273, 280, and 274, respectively. A single asterisk indicates P &lt;0.05 versus placebo; a double asterisk indicates P&lt;0.01 versus placebo.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Chesnut, CH, Silverman, S, Andriano, K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 2000; 109:267.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_55_25470=[""].join("\n");
var outline_f24_55_25470=null;
var title_f24_55_25471="Med bronchogen cyst CT I";
var content_f24_55_25471=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mediastinal subcarinal bronchogenic cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan proves the cystic nature of the subcarinal mass that bulges to the right into azygoesophageal recess.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_55_25471=[""].join("\n");
var outline_f24_55_25471=null;
